研究活動

研究業績

論文

2024年 | 2023年 | 2022年 | 2021年 | 2020年 | 2019年 | 2018年 | 2017年 | 2016年 | 2015年 | 2014年 | 2013年 | 2012年 | 2011年 | 2010年
 2009年 | 2008年 | 2007年 | 2006年 | 2005年 | 2004年 | 2003年 | 2002年 | 2001年 | 2000年

総説

2023年 | 2022年 | 2021年 | 2020年 | 2019年 | 2018年 | 2017年 | 2015年 | 2014年 | 2013年 | 2012年 | 2011年 | 2010年
 2009年 | 2008年 | 2007年 | 2006年 | 2005年 | 2004年 | 2003年 | 2002年 | 2001年 | 2000年

論文

2024

Chiba S, Maemura T, Loeffler K, Frey SJ, Gu C, Biswas A, Hatta M, Kawaoka Y, Kane RS. Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity. Bioeng Transl Med 9(5):e10689. doi: 10.1002/btm2.10689. 2024.
Tanaka R, Tamao K, Ono M, Yamayoshi S, Kawaoka Y, Su'etsugu M, Noji H, Tabata KV. In vitro one-pot construction of influenza viral genomes for virus particle synthesis based on reverse genetics system. PLoS One 19(11):e0312776. doi: 10.1371/journal.pone.0312776. 2024.
Zhou NE, Tang S, Bian X, Parai MK, Krieger IV, Flores A, Jaiswal PK, Bam R, Wood JL, Shi Z, Stevens LJ, Scobey T, Diefenbacher MV, Moreira FR, Baric TJ, Acharya A, Shin J, Rathi MM, Wolff KC, Riva L, Bakowski MA, McNamara CW, Catanzaro NJ, Graham RL, Schultz DC, Cherry S, Kawaoka Y, Halfmann PJ, Baric RS, Denison MR, Sheahan TP, Sacchettini JC. An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo. Cell Rep doi: 10.1016/j.celrep.2024.114929.
Kuwata T, Kaku Y, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Uraki R, Okazaki K, Minami R, Nagasaki Y, Nagashima M, Yoshida I, Sadamasu K, Yoshimura K, Ito M, Kiso M, Yamayoshi S, Imai M, Ikeda T, Sato K, Toyoda M, Ueno T, Inoue T, Tanaka Y, Kimura KT, Hashiguchi T, Sugita Y, Noda T, Morioka H, Kawaoka Y, Matsushita S; Genotype to Phenotype Japan (G2P-Japan) Consortium. Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection case. EBioMedicine doi: 10.1016/j.ebiom.2024.105439.
Chiba S, Kiso M, Yamada S, Someya K, Onodera Y, Yamaguchi A, Matsunaga S, Jounai N, Yamayoshi S, Takeshita F, Kawaoka Y. Protective effects of an mRNA vaccine candidate encoding H5HA clade 2.3.4.4b against the newly emerged dairy cattle H5N1 virus. EBioMedicine 109:105408. doi: 10.1016/j.ebiom.2024.105408. 2024.
Chiba S, Kiso M, Yamada S, Someya K, Onodera Y, Yamaguchi A, Matsunaga S, Uraki R, Iwatsuki-Horimoto K, Yamayoshi S, Takeshita F, Kawaoka Y. An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection. NPJ Vaccines 9(1):189. doi: 10.1038/s41541-024-00988-9. 2024.
Gu C, Maemura T, Guan L, Eisfeld AJ, Biswas A, Kiso M, Uraki R, Ito M, Trifkovic S, Wang T, Babujee L, Presler R Jr, Dahn R, Suzuki Y, Halfmann PJ, Yamayoshi S, Neumann G, Kawaoka Y. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature doi: 10.1038/s41586-024-08254-7. (in press)
Kiso M, Uraki R, Yamayoshi S, Imai M, Kawaoka Y. Drug susceptibility and the potential for drug-resistant SARS-CoV-2 emergence in immunocompromised animals. iScience 27(9):110729. doi: 10.1016/j.isci.2024.110729. 2024.
Hoxie I, Vasilev K, Clark JJ, Bushfield K, Francis B, Loganathan M, Campbell JD, Yu D, Guan L, Gu C, Fan S, Tompkins SM, Neumann G, Kawaoka Y, Krammer F. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters. Vaccine 42(24):126269. doi: 10.1016/j.vaccine.2024.126269. 2024.
Hattori SI, Bulut H, Hayashi H, Kishimoto N, Takamune N, Hasegawa K, Furusawa Y, Yamayoshi S, Murayama K, Tamamura H, Li M, Wlodawer A, Kawaoka Y, Misumi S, Mitsuya H. Structural and virologic mechanism of the emergence of resistance to M^pro inhibitors in SARS-CoV-2. Proc Natl Acad Sci U S A 121(37):e2404175121. doi: 10.1073/pnas.2404175121. 2024.
Eiden J, Fierro C, White A, Davis M, Rhee M, Turner M, Murray B, Herber R, Aitchison R, Marshall D, Moser MJ, Belshe R, Greenberg H, Coelingh K, Kawaoka Y, Neumann G, Bilsel P. Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial. Lancet Infect Dis 24(10):1118-1129. doi: 10.1016/S1473-3099(24)00351-7. 2024.
Eisfeld AJ, Biswas A, Guan L, Gu C, Maemura T, Trifkovic S, Wang T, Babujee L, Dahn R, Halfmann PJ, Barnhardt T, Neumann G, Suzuki Y, Thompson A, Swinford AK, Dimitrov KM, Poulsen K, Kawaoka Y. Pathogenicity and transmissibility of bovine H5N1 influenza virus. Nature 633(8029):426-432. doi: 10.1038/s41586-024-07766-6. 2024.
Takashita E, Ichikawa M, Fujisaki S, Morita H, Nagata S, Miura H, Watanabe S, Hasegawa H, Kawaoka Y. Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. Int J Infect Dis 146:107134. doi: 10.1016/j.ijid.2024.107134. 2024.
Shimizu K, Kawakami C, Matsuzaki Y, Fujisaki S, Nagata S, Morita H, Watanabe K, Miura H, Momoki T, Saikusa M, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Senda R, Okubo I, Watanabe S, Hasegawa H, Kawaoka Y, Takashita E. Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023. Influenza Other Respir Viruses 18(6):e13345. doi: 10.1111/irv.13345. 2024.
Petrie JG, Pattinson D, King JP, Neumann G, Guan L, Jester P, Rolfes MA, Meece JK, Kieke BA, Belongia EA, Kawaoka Y, Nguyen HQ. SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020 - July 2022. Am J Epidemiol doi: 10.1093/aje/kwae125. 2024.
Guan L, Eisfeld AJ, Pattinson D, Gu C, Biswas A, Maemura T, Trifkovic S, Babujee L, Presler R Jr, Dahn R, Halfmann PJ, Barnhardt T, Neumann G, Thompson A, Swinford AK, Dimitrov KM, Poulsen K, Kawaoka Y. Cow’s milk containing avian influenza A (H5N1) virus – heat inactivation and infectivity in mice. N Engl J Med 391(1):87-90. doi: 10.1056/NEJMc2405495. 2024.
Fukuyama S, Shoemaker JE, Zhao D, Nagajima N, Tomita Y, Maemura T, Lopes TJS, Watanabe T, Yamayoshi S, Hasegawa H, Kawaoka Y. Attenuation of A(H7N9) influenza virus infection in mice exposed to cigarette smoke. NPJ Viruses 2:16. doi: 10.1038/s44298-024-00026-4. 2024.
Mühlemann B, Wilks SH, Baracco L, Bekliz M, Carreño JM, Corman VM, Davis-Gardner ME, Dejnirattisai W, Diamond MS, Douek DC, Drosten C, Eckerle I, Edara VV, Ellis M, Fouchier RAM, Frieman M, Godbole S, Haagmans B, Halfmann PJ, Henry AR, Jones TC, Katzelnick LC, Kawaoka Y, Kimpel J, Krammer F, Lai L, Liu C, Lusvarghi S, Meyer B, Mongkolsapaya J, Montefiori DC, Mykytyn A, Netzl A, Pollett S, Rössler A, Screaton GR, Shen X, Sigal A, Simon V, Subramanian R, Supasa P, Suthar MS, Türeli S, Wang W, Weiss CD, Smith DJ. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays. Sci Transl Med 16(747):eadl1722. doi: 10.1126/scitranslmed.adl1722. 2024.
Ueki H, Kiso M, Furusawa Y, Iida S, Yamayoshi S, Nakajima N, Imai M, Suzuki T, Kawaoka Y. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging. Viruses 16(4):537. doi: 10.3390/v16040537. 2024.
Pattinson D, Jester P, Gu C, Guan L, Armbrust T, Petrie JG, King JP, Nguyen HQ, Belongia EA, Halfmann P, Neumann G, Kawaoka Y. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses. EBioMedicine 103:105103. doi: 10.1016/j.ebiom.2024.105103. 2024.
Eisfeld AJ, Anderson LN, Fan S, Walters KB, Halfmann PJ, Westhoff Smith D, Thackray LB, Tan Q, Sims AC, Menachery VD, Schäfer A, Sheahan TP, Cockrell AS, Stratton KG, Webb-Robertson BM, Kyle JE, Burnum-Johnson KE, Kim YM, Nicora CD, Peralta Z, N'jai AU, Sahr F, van Bakel H, Diamond MS, Baric RS, Metz TO, Smith RD, Kawaoka Y, Waters KM. A compendium of multi-omics data illuminating host responses to lethal human virus infections. Sci Data 11(1):328. doi: 10.1038/s41597-024-03124-3. 2024.
Guan L, Babujee L, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, Bakel HV, Kawaoka Y, Neumann G. Avian H6 Influenza Viruses in Vietnamese Live Bird Markets during 2018-2021. Viruses 16(3):367. doi: 10.3390/v16030367. 2024.
Hill-Batorski L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, Matejka SM, Marshall D, Kawaoka Y, Neumann G, Bilsel P. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge. Vaccine 42(11):2770-2780. doi: 10.1016/j.vaccine.2024.03.040. 2024.
Shafer MM, Bobholz MJ, Vuyk WC, Gregory DA, Roguet A, Haddock Soto LA, Rushford C, Janssen KH, Emmen IE, Ries HJ, Pilch HE, Mullen PA, Fahney RB, Wei W, Lambert M, Wenzel J, Halfmann P, Kawaoka Y, Wilson NA, Friedrich TC, Pray IW, Westergaard R, O'Connor DH, Johnson MC. Tracing the origin of SARS-CoV-2 omicron-like spike sequences detected in an urban sewershed: a targeted, longitudinal surveillance study of a cryptic wastewater lineage. Lancet Microbe 5(4):e335-e344. doi: 10.1016/S2666-5247(23)00372-5. 2024.
Halfmann PJ, Iwatsuki-Horimoto K, Kuroda M, Hirata Y, Yamayoshi S, Iida S, Uraki R, Ito M, Ueki H, Furusawa Y, Sakai-Tagawa Y, Kiso M, Armbrust T, Spyra S, Maeda K, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Commun Biol 7(1):331. doi: 10.1038/s42003-024-06015-w. 2024.
Gu C, Fan S, Dahn R, Babujee L, Chiba S, Guan L, Maemura T, Pattinson D, Neumann G, Kawaoka Y. Characterization of a human H3N8 influenza virus. EBioMedicine 101:105034. doi: 10.1016/j.ebiom.2024.105034. 2024.
Fan S, Kong H, Babujee L, Presler R Jr, Jester P, Burke D, Pattinson D, Barr I, Smith D, Neumann G, Kawaoka Y. Assessment of the antigenic evolution of a clade 6B.1 human H1N1pdm influenza virus revealed differences between ferret and human convalescent sera. EBioMedicine 101:105013. doi: 10.1016/j.ebiom.2024.105013. 2024.
Halfmann PJ, Loeffler K, Duffy A, Kuroda M, Yang JE, Wright ER, Kawaoka Y, Kane RS. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat Commun 15(1):1284. doi: 10.1038/s41467-024-45495-6. 2024.
Yamayoshi S, Nagai E, Mitamura K, Hagihara M, Kobayashi R, Takahashi S, Shibata A, Uwamino Y, Hasegawa N, Iqbal A, Kamimaki I, Iwatsuki-Horimoto K, Nagamura-Inoue T, Kawaoka Y. Seroprevalence of SARS-CoV-2 N antibodies between December 2021 and March 2023 in Japan Epidemiol Infect 152:e24. doi: 10.1017/S0950268824000141. 2024.
Maruki T, Nomoto H, Iwamoto N, Yamamoto K, Kurokawa M, Iwatsuki-Horimoto K, Yamayoshi S, Suzuki Y, Kawaoka Y, Ohmagari N. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. J Infect Chemother 30(8):793-795. doi: 10.1016/j.jiac.2024.01.008. 2024.
Ishizaka A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV. BMC Microbiol 24(1):6. doi: 10.1186/s12866-023-03157-5. 2024.
Hagihara M, Hayashi H, Nakashima S, Imai Y, Nakano H, Uchida T, Inoue M, Sakai-Tagawa Y, Ito M, Yamayoshi S, Iwatsuki-Horimoto K, Suzuki Y, Kawaoka Y. Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies. Intern Med 63(16):2283-2287. doi: 10.2169/internalmedicine.2900-23. 2024.
Uraki R, Imai M, Ito M, Yamayoshi S, Kiso M, Jounai N, Miyaji K, Iwatsuki-Horimoto K, Takeshita F, Kawaoka Y. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants. NPJ Vaccines 9(1):4. doi: 10.1038/s41541-023-00800-0. 2024.
Whitworth IT, Knoener RA, Puray-Chavez M, Halfmann P, Romero S, Baddouh M, Scalf M, Kawaoka Y, Kutluay SB, Smith LM, Sherer NM. Defining Distinct RNA-Protein Interactomes of SARS-CoV-2 Genomic and Subgenomic RNAs. J Proteome Res 23(1):149-160. doi: 10.1021/acs.jproteome.3c00506. 2024.
Belongia EA, Petrie JG, Feldstein LR, Guan L, Halfmann PJ, King JP, Neumann G, Pattinson D, Rolfes MA, McLean HQ, Kawaoka Y. Neutralizing Immunity Against Antigenically Advanced Omicron BA.5 in Children After SARS-CoV-2 Infection. J Pediatric Infect Dis Soc. 13(1):100-104. doi: 10.1093/jpids/piad109. 2024.

2023

Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 42(12):113580. doi: 10.1016/j.celrep.2023.113580. 2023.
Iwatsuki-Horimoto K, Ito M, Okuda-Hamabata M, Takagi H, Imai M, Kawaoka Y. Cardiomyopathy does not exacerbate the severity of pneumonia caused by a SARS-CoV-2 delta variant in the J2N-k hamster model. Viruses 15(12):2280. doi: 10.3390/v15122280. 2023.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Fukushi S, Watanabe S, Suzuki T, Kikuchi T, Yotsuyanagi H, Maeda K, Kawaoka Y. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience 26(11):108147. doi: 10.1016/j.isci.2023.108147. 2023.
Maemura T, Guan L, Gu C, Eisfeld A, Biswas A, Halfmann P, Neumann G, Kawaoka Y. Characterization of highly pathogenic clade 2.3.4.4b H5N1 mink influenza viruses. EBioMedicine 97:104827. doi: 10.1016/j.ebiom.2023.104827. 2023.
Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, Caniza MA, Chacaltana-Huarcaya JN, Corman VM, Daniell X, Datto MB, Dawood FS, Denny TN, Drosten C, Fouchier RAM, Garcia PJ, Halfmann PJ, Jassem A, Jeworowski LM, Jones TC, Kawaoka Y, Krammer F, McDanal C, Pajon R, Simon V, Stockwell MS, Tang H, van Bakel H, Veguilla V, Webby R, Montefiori DC, Smith DJ. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science 382(6666):eadj0070. doi: 10.1126/science.adj0070. 2023.
Kingstad-Bakke B, Cleven T, Bussan H, Yount BL Jr, Uraki R, Iwatsuki-Horimoto K, Koga M, Yamamoto S, Yotsuyanagi H, Park H, Mishra JS, Kumar S, Baric R, Halfmann PJ, Kawaoka Y, Suresh M. Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine. JCI Insight 8(22):e172510. doi: 10.1172/jci.insight.172510. 2023.
Kikuchi C, Antonopoulos A, Wang S, Maemura T, Karamanska R, Lee C, Thompson AJ, Dell A, Kawaoka Y, Haslam SM, Paulson JC. Glyco-engineered MDCK cells display preferred receptors of H3N2 influenza absent in eggs used for vaccines. Nat Commun 14(1):6178. doi: 10.1038/s41467-023-41908-0. 2023.
Hou YJ, Chiba S, Leist SR, Meganck RM, Martinez DR, Schäfer A, Catanzaro NJ, Sontake V, West A, Edwards CE, Yount B, Lee RE, Gallant SC, Zost SJ, Powers J, Adams L, Kong EF, Mattocks M, Tata A, Randell SH, Tata PR, Halfmann P, Crowe JE Jr, Kawaoka Y, Baric RS. Host range, transmissibility and antigenicity of a pangolin coronavirus. Nat Microbiol 8(10):1820-1833. doi: 10.1038/s41564-023-01476-x. 2023.
Halfmann PJ, Minor NR, Haddock Iii LA, Maddox R, Moreno GK, Braun KM, Baker DA, Riemersa KK, Prasad A, Alman KJ, Lambert MC, Florek K, Bateman A, Westergaard R, Safdar N, Andes DR, Kawaoka Y, Fida M, Yao JD, Friedrich TC, O'Connor DH. Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol 9(2):veac104. doi: 10.1093/ve/veac104. 2023.
Chiba S, Halfmann PJ, Iida S, Hirata Y, Sato Y, Kuroda M, Armbrust T, Spyra S, Suzuki T, Kawaoka Y. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. Vaccine 41(41):6025-6035. doi: 10.1016/j.vaccine.2023.08.054. 2023.
Guan L, Ping J, Lopes TJS, Fan S, Presler R, Neumann G, Kawaoka Y. Development of an Enhanced High-Yield Influenza Vaccine Backbone in Embryonated Chicken Eggs. Vaccines (Basel) 11(8):1364. doi: 10.3390/vaccines11081364. 2023.
Kuroda M, Halfmann PJ, Kawaoka Y. Ebola virus infection induces HCAR2 expression leading to cell death. J Infect Dis 228 Suppl 7:S508-S513. doi: 10.1093/infdis/jiad344. 2023.
Kuroda M, Halfmann PJ, Thackray LB, Diamond MS, Feldmann H, Marzi A, Kawaoka Y. An antiviral role for TRIM14 in Ebola virus infection. J Infect Dis 228 Suppl 7:S514-S521. doi: 10.1093/infdis/jiad325. 2023.
Guan L, Babujee L, Browning VL, Presler R, Pattinson D, Nguyen HLK, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Continued Circulation of Highly Pathogenic H5 Influenza Viruses in Vietnamese Live Bird Markets in 2018-2021. Viruses 15(7):1596. doi: 10.3390/v15071596. 2023.
Chiba S, Kong H, Neumann G, Kawaoka Y. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes. mBio 14(4):e0062223. doi: 10.1128/mbio.00622-23. 2023.
Kiso M, Yamayoshi S, Iida S, Furusawa Y, Hirata Y, Uraki R, Imai M, Suzuki T, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nat Commun 14(1):4231. doi: 10.1038/s41467-023-40018-1. 2023.
Takashita E, Fujisaki S, Morita H, Nagata S, Miura H, Nagashima M, Watanabe S, Takeda M, Kawaoka Y, Hasegawa H. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors. Antiviral Res 216:105671. doi: 10.1016/j.antiviral.2023.105671. 2023.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. iScience 26(7):107208. doi: 10.1016/j.isci.2023.107208. 2023.
Ishizaka A, Koga M, Mizutani T, Uraki R, Yamayoshi S, Iwatsuki-Horimoto K, Yamamoto S, Imai M, Tsutsumi T, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol J 20(1):146. doi: 10.1186/s12985-023-02113-z. 2023.
Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat Commun 14(1):3952. doi: 10.1038/s41467-023-39704-x. 2023.
Halfmann PJ, Borisevich V, Levine CB, Mire CE, Fenton KA, Geisbert TW, Kawaoka Y, Cross RW. The Mucin-like Domain of the Ebola Glycoprotein Does Not Impact Virulence or Pathogenicity in Ferrets. J Infect Dis 228(Supplement_7):S587-S593. doi: 10.1093/infdis/jiad240. 2023.
Moser MJ, Hill-Batorski L, Bowen RA, Matejka SM, Marshall D, Kawaoka Y, Neumann G, Bilsel P. Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants. Vaccines (Basel) 11(6):1063. doi: 10.3390/vaccines11061063. 2023.
Yamayoshi S, Ito M, Iwatsuki-Horimoto K, Yasuhara A, Okuda M, Hamabata T, Murakami J, Duong C, Yamamoto T, Kuroda Y, Maeda K, Kawaoka Y. Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan. One Health 17:100588. doi: 10.1016/j.onehlt.2023.100588. 2023.
Halfmann PJ, Uraki R, Kuroda M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Kawaoka Y. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters. EBioMedicine 93:104677. doi: 10.1016/j.ebiom.2023.104677. 2023.
Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Lin Q, Sakuma M, Kawahara E, Yamazaki I, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Hisano T, Moriyama S, Takahashi Y, Ito M, Imai M, Maemura T, Furusawa Y, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner Project. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents. iScience 26(6):106955. doi: 10.1016/j.isci.2023.106955. 2023.
Guan L, Zhong G, Fan S, Plisch EM, Presler R, Gu C, Babujee L, Pattinson D, Le Khanh Nguyen H, Hoang VMP, Le MQ, van Bakel H, Neumann G, Kawaoka Y. Highly Pathogenic H5 Influenza Viruses Isolated between 2016 and 2017 in Vietnamese Live Bird Markets. Viruses. 15(5):1093. doi: 10.3390/v15051093. 2023.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Theiler J, Yotsuyanagi H, Suzuki Y, Korber B, Kawaoka Y. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate. Lancet Reg Health West Pac 34:100777. doi: 10.1016/j.lanwpc.2023.100777. 2023.
Kiso M, Yamayoshi S, Kawaoka Y. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors. J Antimicrob Chemother 78(7):1649-1657. doi: 10.1093/jac/dkad145. 2023.
Sakai-Tagawa Y, Yamayoshi S, Halfmann PJ, Wilson N, Bobholz M, Vuyk WC, Wei W, Ries H, O'Connor DH, Friedrich TC, Sordillo EM, van Bakel H, Simon V, Kawaoka Y. Sensitivity of rapid antigen tests for Omicron subvariants of SARS-CoV-2. J Med Virol 95(5):e28788. doi: 10.1002/jmv.28788. 2023.
Hill-Batorski L, Hatta Y, Moser MJ, Sarawar S, Neumann G, Kawaoka Y, Bilsel P. Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge. Vaccines (Basel) 11(4):798. doi: 10.3390/vaccines11040798. 2023.
Muramoto Y, Takahashi S, Halfmann PJ, Gotoh S, Noda T, Kawaoka Y. Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures. Lancet Microbe 4(7):e486. doi: 10.1016/S2666-5247(23)00100-3. 2023.
Furusawa Y, Kiso M, Iida S, Uraki R, Hirata Y, Imai M, Suzuki T, Yamayoshi S, Kawaoka Y.　In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters.　EBioMedicine 91:104561. doi: 10.1016/j.ebiom.2023.104561. 2023
Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun 14(1):1620. doi: 10.1038/s41467-023-37059-x. 2023.
Tamura D, Kawaoka Y. Omicron proliferation in the nasal cavity may explain its high infectivity. J Infect 86(6):584-587. doi: 10.1016/j.jinf.2023.03.006. 2023
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1. Lancet Infect Dis 23(5):525-526. doi: 10.1016/S1473-3099(23)00132-9. 2023.
Furusawa Y, Yamayoshi S, Kawaoka Y. The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome. Influenza Other Respir Viruses 17(3):e13109. doi: 10.1111/irv.13109. 2023.
Bramer LM, Hontz RD, Eisfeld AJ, Sims AC, Kim YM, Stratton KG, Nicora CD, Gritsenko MA, Schepmoes AA, Akasaka O, Koga M, Tsutsumi T, Nakamura M, Nakachi I, Baba R, Tateno H, Suzuki S, Nakajima H, Kato H, Ishida K, Ishii M, Uwamino Y, Mitamura K, Paurus VL, Nakayasu ES, Attah IK, Letizia AG, Waters KM, Metz TO, Corson K, Kawaoka Y, Gerbasi VR, Yotsuyanagi H, Iwatsuki-Horimoto K. Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections. Heliyon 9(3):e13795. doi: 10.1016/j.heliyon.2023.e13795. 2023.
Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Belongia EA, McLean HQ. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022. Influenza Other Respir Viruses 17(3):e13104. doi: 10.1111/irv.13104. 2023.
Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, Li L, Wilbanks GD, Kuroda M, Maemura T, Huang M, Zheng NY, Turner HL, Erickson SA, Fu Y, Yasuhara A, Singh G, Monahan B, Mauldin J, Srivastava K, Simon V, Krammer F, Sather DN, Ward AB, Wilson IA, Kawaoka Y, Wilson PC. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct Omicron subvariants. J Clin Invest 133(8):e166844. doi: 10.1172/JCI166844. 2023.
Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y. Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in Japan.　Viruses 15(2):535. doi: 10.3390/v15020535. 2023.
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nat Commun 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0. 2023.
McLean HQ, Petrie JG, Hanson KE, Meece JK, Rolfes MA, Sylvester GC, Neumann G, Kawaoka Y, Belongia EA. Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023. MMWR Morb Mortal Wkly Rep 72(8):201-205. doi: 10.15585/mmwr.mm7208a1. 2023.
Braun KM, Haddock Iii LA, Crooks CM, Barry GL, Lalli J, Neumann G, Watanabe T, Imai M, Yamayoshi S, Ito M, Moncla LH, Koelle K, Kawaoka Y, Friedrich TC. Avian H7N9 influenza viruses are evolutionarily constrained by stochastic processes during replication and transmission in mammals. Virus Evol 9(1):vead004. doi: 10.1093/ve/vead004. 2023.
Nakayama T, Azegami T, Kiso M, Imai M, Uraki R, Hayashi K, Hishikawa A, Yoshimoto N, Nakamichi R, Sugita-Nishimura E, Yoshida-Hama E, Kawaoka Y, Itoh H. Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection. Sci Rep 13(1):3103. doi: 10.1038/s41598-023-30305-8. 2023.
Mahita J, Ha B, Gambiez A, Schendel SL, Li H, Hastie KM, Dennison SM, Li K, Kuzmina N, Periasamy S, Bukreyev A, Munt JE, Osei-Twum M, Atyeo C, Overton JA, Vita R, Guzman-Orozco H, Mendes M, Kojima M, Halfmann PJ, Kawaoka Y, Alter G, Gagnon L, Baric RS, Tomaras GD, Germann T, Bedinger D, Greenbaum JA, Saphire EO, Peters B. Coronavirus Immunotherapeutic Consortium Database. Database (Oxford) 2023:baac112. doi: 10.1093/database/baac112. 2023.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann P, Pekosz A, Kawaoka Y. Antiviral and Bivalent Vaccine Efficacy against an Omicron XBB.1.5 isolate. Lancet Inf Dis 23(4):402-403. doi: 10.1016/S1473-3099(23)00070-1. 2023.
Saitoh H, Sakai-Tagawa Y, Nagasawa S, Torimitsu S, Kubota K, Hirata Y, Iwatsuki-Horimoto K, Motomura A, Ishii N, Okaba K, Horioka K, Abe H, Ikemura M, Rokutan H, Hinata M, Iwasaki A, Yasunaga Y, Nakajima M, Yamaguchi R, Tsuneya S, Kira K, Kobayashi S, Inokuchi G, Chiba F, Hoshioka Y, Mori A, Yamamoto I, Nakagawa K, Katano H, Iida S, Suzuki T, Akitomi S, Hasegawa I, Ushiku T, Yajima D, Iwase H, Makino Y, Kawaoka Y. High titers of infectious SARS-CoV-2 in COVID-19 corpses. Int J Infect Dis 129:103-109. doi: 10.1016/j.ijid.2023.01.046. 2023.
Iwatsuki-Horimoto K, Ueki H, Ito M, Nagasawa S, Hirata Y, Hashizume K, Ushiwata K, Iwase H, Makino Y, Ushiku T, Akitomi S, Imai M, Saitoh H, Kawaoka Y. SARS-CoV-2 Transmission from Virus-Infected Dead Hamsters. mSphere 8(1):e0041122. doi: 10.1128/msphere.00411-22. 2023.
Takashita E, Watanabe S, Hasegawa H, Kawaoka Y. Are twindemics occurring? Influenza Other Respir Viruses 17(1):e13090. doi: 10.1111/irv.13090. 2023.
Chen S, Quan DH, Sam G, Ozberk V, Wang XT, Halfmann P, Pandey M, Good MF, Kawaoka Y, Britton WJ, Rehm BHA. Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines. Small 19(8):e2205819. doi: 10.1002/smll.202205819. 2023.
Chiba S, Hatta M, Pattinson D, Yasuhara A, Neumann G, Kawaoka Y. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses. Vaccine 41(2):590-597. doi: 10.1016/j.vaccine.2022.12.005. 2023.
Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect Dis 23(1):30-32. doi: 10.1016/S1473-3099(22)00816-7. 2023.

2022

Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 388(1):89-91. doi: 10.1056/NEJMc2214302. 2022.
Sarawar S, Gabaglia CR, Sanchez A, Hatta Y, Dias P, Neumann G, Kawaoka Y, Bilsel P. Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice. Vaccines (Basel) 10(12):2131. doi: 10.3390/vaccines10122131. 2022.
Boon ACM, Darling TL, Halfmann PJ, Franks J, Webby RJ, Barouch DH, Port JR, Munster VJ, Diamond MS, Kawaoka Y. Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters. PLoS Pathog 18(12):e1010970. doi: 10.1371/journal.ppat.1010970. 2022.
Murakami S, Kitamura T, Matsugo H, Kamiki H, Oyabu K, Sekine W, Takenaka-Uema A, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. Isolation of Bat Sarbecoviruses, Japan. Emerg Infect Dis 28(12):2500-2503. doi: 10.3201/eid2812.220801. 2022.
Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Moriyama S, Takahashi Y, Ishigaki H, Nakayama M, Nguyen CT, Kitagawa Y, Itoh Y, Imai M, Maemura T, Furusawa Y, Ueki H, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner Project. Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models. iScience 25(12):105596. doi: 10.1016/j.isci.2022.105596. 2022.
Halfmann PJ, Frey SJ, Loeffler K, Kuroda M, Maemura T, Armbrust T, Yang JE, Hou YJ, Baric R, Wright ER, Kawaoka Y, Kane RS. Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine 86:104341. doi: 10.1016/j.ebiom.2022.104341. 2022.
Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. N Engl J Med 387(22):2094-2097. doi: 10.1056/NEJMc2211845. 2022.
Eiden J, Fierro C, Schwartz H, Adams M, Ellis KJ, Aitchison R, Herber R, Hatta Y, Marshall D, Moser MJ, Belshe R, Greenberg H, Coelingh K, Kawaoka Y, Neumann G, Bilsel P. Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults. J Infect Dis 227(1):103-112. doi: 10.1093/infdis/jiac433. 2022.
Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat Commun 13(1):6602. doi: 10.1038/s41467-022-34521-0. 2022.
Ohta M, Kambayashi Y, Mita H, Kuroda T, Bannai H, Tsujimura K, Yamanaka T, Garvey M, Cullinane A, Yamayoshi S, Kawaoka Y, Nemoto M. Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses. Vaccine 40(44):6362-6366. doi: 10.1016/j.vaccine.2022.09.047. 2022.
Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612(7940):540-545. doi: 10.1038/s41586-022-05482-7. 2022
Suthar MS, Arunachalam PS, Hu M, Reis N, Trisal M, Raeber O, Chinthrajah S, Davis-Gardner ME, Manning K, Mudvari P, Boritz E, Godbole S, Henry AR, Douek DC, Halfmann P, Kawaoka Y, Boyd SD, Davis MM, Zarnitsyna VI, Nadeau K, Pulendran B. Durability of immune responses to the BNT162b2 mRNA vaccine. Med (N Y) 3(1):25-27. doi: 10.1016/j.medj.2021.12.005. 2022.
Riemersma KK, Haddock LA 3rd, Wilson NA, Minor N, Eickhoff J, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH, Friedrich TC, Grande KM. Shedding of infectious SARS-CoV-2 despite vaccination. PLoS Pathog 18(9):e1010876. doi: 10.1371/journal.ppat.1010876. 2022.
Meng F, Yang H, Qu Z, Chen Y, Zhang Y, Zhang Y, Liu L, Zeng X, Li C, Kawaoka Y, Chen H.　A Eurasian avian-like H1N1 swine influenza reassortant virus became pathogenic and highly transmissible due to mutations in its PA gene. Proc Natl Acad Sci U S A 119(34):e2203919119. doi: 10.1073/pnas.2203919119. 2022.
Koga M, Iwatsuki-Horimoto K, Kikuchi T, Yamayoshi S, Kawaoka Y, Yotsuyanagi H. Previous Omicron infection may be protective against reinfection with Omicron variant BA.5 for at least five months. Clin Microbiol Infect 29(1):120-121. doi: 10.1016/j.cmi.2022.09.009. 2023.
Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020–March 2022, Japan. Emerg Infect Dis 28(11):2198-2205. doi: 10.3201/eid2811.221127. 2022.
Eiden J, Volckaert B, Rudenko O, Aitchison R, Herber R, Belshe R, Greenberg H, Coelingh K, Marshall D, Kawaoka Y, Neumann G, Bilsel P. M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain. J Infect Dis 226(1):83-90. doi: 10.1093/infdis/jiab374. 2022.
Ueki H, Ujie M, Komori Y, Kato T, Imai M, Kawaoka Y. Effectiveness of HEPA Filters at Removing Infectious SARS-CoV-2 from the Air. mSphere 7(4):e0008622. doi: 10.1128/msphere.00086-22. 2022.
Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veesler D, Corti D. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602(7898):664-670. doi: 10.1038/s41586-021-04386-2. 2022.
Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, Takashita E, Ujie M, Furusawa Y, Yasuhara A, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Watanabe S, Hasegawa H, Kawaoka Y. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters. Nat Microbiol 7(8):1252-1258. doi: 10.1038/s41564-022-01170-4, 2022.
Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y. Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N Engl J Med 387(13):1236-1238. doi: 10.1056/NEJMc2209952. 2022.
Fan S, Gu C, Kong H, Guan L, Neumann G, Kawaoka Y. Influenza Viruses Suitable for Studies in Syrian Hamsters. Viruses. 14(8):1629, 2022.
Byrd-Leotis L, Jia N, Matsumoto Y, Lu D, Kawaoka Y, Steinhauer DA, Cummings RD. Sialylated and sulfated N-Glycans in MDCK and engineered MDCK cells for influenza virus studies. Sci Rep 12(1):12757, 2022
Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med 387(5):468-470. doi: 10.1056/NEJMc2207519. 2022.
Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy. Jpn J Infect Dis 75(6):608-611. doi: 10.7883/yoken.JJID.2022.092. 2022.
Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, Guarino B, Schmid MA, Rosenthal K, Ren K, Dang HV, Snell G, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe JE Jr, Fremont DH, Virgin HW, Loo YM, Esser MT, Purcell LA, Corti D, Diamond MS. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun 13(1):3824, 2022.
Belser JA, Lau EHY, Barclay W, Barr IG, Chen H, Fouchier RAM, Hatta M, Herfst S, Kawaoka Y, Lakdawala SS, Lee LYY, Neumann G, Peiris M, Perez DR, Russell C, Subbarao K, Sutton TC, Webby RJ, Yang H, Yen HL; Working group on the standardization of the ferret model for influenza risk assessment. Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise. mBio e0117422, 2022.
Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N. Parsing the role of NSP1 in SARS-CoV-2 infection. Cell Rep 39(11):110954, 2022.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607(7917):119-127, doi: 10.1038/s41586-022-04856-1, 2022.
Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Sci Transl Med. 14(657):eabm4908. doi: 10.1126/scitranslmed.abm4908, 2022.
Darling TL, Ying B, Whitener B, VanBlargan LA, Bricker TL, Liang CY, Joshi A, Bamunuarachchi G, Seehra K, Schmitz AJ, Halfmann PJ, Kawaoka Y, Elbashir SM, Edwards DK, Thackray LB, Diamond MS, Boon ACM. mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. Med (N Y). 3(5):309-324.e6. doi: 10.1016/j.medj.2022.03.009. 2022.
Chong Z, Karl CE, Halfmann PJ, Kawaoka Y, Winkler ES, Keeler SP, Holtzman MJ, Yu J, Diamond MS. Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Rep. 2022 39(6):110799, 2022.
Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Lim LA, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Immunological correlates of prevention of the onset of seasonal H3N2 influenza. J Infect Dis. 226(10):1800-1808. doi: 10.1093/infdis/jiac152, 2022.
Ueki H, Ito M, Furusawa Y, Yamayoshi S, Inoue SI, Kawaoka Y. A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols. mSphere 7:e0094121. doi: 10.1128/msphere.00941-21. 2022.
Murakami J, Shibata A, Neumann G, Imai M, Watanabe T, Kawaoka Y. Characterization of H9N2 Avian Influenza Viruses Isolated from Poultry Products in a Mouse Model. Viruses. 14:728. 2022.
Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Rep. 39(3):110688, 2022.
Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan. Intern Med 61(11):1681-1686. doi: 10.2169/internalmedicine.9209-21, 2022.
Pattinson D, Jester P, Guan L, Yamayoshi S, Chiba S, Presler R, Rao H, Iwatsuki-Horimoto K, Ikeda N, Hagihara M, Uchida T, Mitamura K, Halfmann P, Neumann G, Kawaoka Y. A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. Viruses 2022 14(3):562, 2022.
McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, Halfmann P, Kawaoka Y, Piedra-Mora C, Jain N, Ducat S, Kar S, Andersen H, Lewis MG, Martinot AJ, Barouch DH. Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. Med (N Y) 3(4):262-268.e4, 2022.
Milligan JC, Davis CW, Yu X, Ilinykh PA, Huang K, Halfmann PJ, Cross RW, Borisevich V, Agans KN, Geisbert JB, Chennareddy C, Goff AJ, Piper AE, Hui S, Shaffer KCL, Buck T, Heinrich ML, Branco LM, Crozier I, Holbrook MR, Kuhn JH, Kawaoka Y, Glass PJ, Bukreyev A, Geisbert TW, Worwa G, Ahmed R, Saphire EO. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185:995-1007, 2022.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med 386(15):1475-1477. doi: 10.1056/NEJMc2201933, 2022.
Mizutani T, Ishizaka A, Koga M, Ikeuchi K, Saito M, Adachi E, Yamayoshi S, Iwatsuki-Horimoto K, Yasuhara A, Kiyono H, Matano T, Suzuki Y, Tsutsumi T, Kawaoka Y, Yotsuyanagi H. Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization. Microbiol Spectr 10(2):e0168921, 2022.
McLean HQ, McClure DL, King JP, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Rolfes MA, Belongia EA. mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. Influenza Other Respir Viruses 16(4):607-612, 2022.
Halfmann PJ, Kuroda M, Armbrust T, Accola M, Valdez R, Kowalski-Dobson T, Rehrauer W, Gordon A, Kawaoka Y. Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. Cell Rep 38:110394, 2022.
Yoshimi K, Takeshita K, Yamayoshi S, Shibumura S, Yamauchi Y, Yamamoto M, Yotsuyanagi H, Kawaoka Y, Mashimo T. CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus. iScience 25:103830, 2022.
VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med 19:1-6, 2022.
Halfmann P, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer S, Darling T, Joshi A, Loeber S, Singh G, Foster S, Ying B, Case J, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio J, Hernandez-Ortiz J, Henry A, Ciouderis K, Florek K, Patel M, Odle A, Wong LY, Bateman A, Wang Z, Edara VV, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche A, Sordillo E, Chang L, Bakel H, Simon V, PSP study group, Douek D, Sullivan N, Thackray L, Ueki H, Yamayoshi S, Imai M, Perlman S, Webby R, Seder R, Suthar M, Garcia-Sastre A, Schotsaert M, Suzuki T, Boon A, Diamond M, KawaokaY. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603:687-692, 2022.
Ohta M, Bannai H, Kambayashi Y, Tsujimura K, Tamura N, Iwamoto Y, Wakuno A, Yamayoshi S, Kawaoka Y, Nemoto M. Antibody Responses to a Reverse Genetics-Derived Bivalent Inactivated Equine Influenza Vaccine in Thoroughbred Horses. J Equine Vet Sci 109:103860, 2022.

2021

Uraki R, Imai M, Ito M, Shime H, Odanaka M, Okuda M, Kawaoka Y, Yamazaki S. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. PLoS Pathog 17:e1010085, 2021.
Kong H, Fan S, Takada K, Imai M, Neumann G, Kawaoka Y. H3N2 Influenza Viruses with 12- or 16-Amino Acid Deletions in the Receptor-Binding Region of Their Hemagglutinin Protein. mBio 12:e0151221, 2021.
Sakai-Tagawa Y, Yamayoshi S, Halfmann P, Kawaoka Y. Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2. Viruses 13: 2183, 2021.
Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K, Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. J Virol 96:e01551-21, 2022.
Ohtsuka J, Imai M, Fukumura M, Maeda M, Eguchi A, Ono R, Maemura T, Ito M, Yamayoshi S, Kataoka Y, Kawaoka Y, Nosaka T. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. iScience 24:103379, 2021.
Chen S, Evert B, Adeniyi A, Salla-Martret M, Lua L, Ozberk V, Pandey M, Good M, Suhrbier A, Halfmann P, Kawaoka Y, Rehm B. Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity. Adv Healthc Mater e2102089, 2022.
Kong X, Guan L, Shi J, Kong H, Zhang Y, Zeng X, Tian G, Liu L, Li C, Kawaoka Y, Deng G, Chen H. A single-amino-acid mutation at position 225 in hemagglutinin attenuates H5N6 influenza virus in mice. Emerg Microbes Infect. 10:2052-2061, 2021.
Navaratnarajah C, Pease D, Halfmann P, Taye B, Barkhymer A, Howell K, Charlesworth J, Christensen T, Kawaoka Y, Cattaneo R, Schneider J. Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. J Virol 95:e01368-21, 2021.
Halfmann P, Castro A, Loeffler K, Frey S, Chiba S, Kawaoka Y, Kane R. Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. Bioeng Transl Med 6:e10253, 2021.
Saito T, Muto K, Tanaka M, Okabe N, Oshitani H, Kamayachi S, Kawaoka Y, Kawana A, Suzuki M, Tateda K, Nakayama H, Yoshida M, Imamura A, Ohtake F, Ohmagari N, Osaka K, Kaku M, Sunagawa T, Nakashima K, Nishiura H, Wada K, Omi S, Wakita T. Proactive Engagement of the Expert Meeting in Managing the Early Phase of the COVID-19 Epidemic, Japan, February-June 2020. Emerg Infect Dis 27(10):1-9, 2021.
Changrob S, Fu Y, Guthmiller J, Halfmann P, Li L, Stamper C, Dugan H, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson S, Utset H, Graves H, Amanat F, Sather DN, Krammer F, Kawaoka Y, Wilson P. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike. mBio 12: e02975-21, 2021.
Chiba S, Kiso M, Nakajima N, Iida S, Maemura T, Kuroda M, Sato Y, Ito M, Okuda M, Yamada S, Iwatsuki-Horimoto K, Watanabe T, Armbrust T, Baric RS, Halfmann PJ, Suzuki T, Kawaoka Y. Co-administration of favipiravir and the remdesivir metabolite GS-441524 effectively reduces virus replication in the lungs of the Syrian hamster model. mBio 13:e0304421, 2022.
Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. mBio 12(5):e0198721. doi: 10.1128/mBio.01987-21. 2021.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Efficacy of antibodies and antivirals against a SARS-CoV-2 Omicron variant. N Engl J Med 386:995-998, 2022.
Halfmann P, Nakajima N, Sato Y, Takahashi K, Accola M, Chibo S, Fan S, Neumann G, Rehrauer W, Suzuki T, Kawaoka Y. SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. J Infect Dis 225:282-286, 2022.
Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M; Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602:300-306, 2022.
Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, Crawford LK. Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats. Vet Pathol 59(4):696-706, 2022.
Eiden J, Volckaert B, Rudenko O, Aitchison R, Herber R, Belshe R, Greenberg H, Coelingh K, Marshall D, Kawaoka Y, Neumann G, Bilsel P. Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain. J Infect Dis 226(1):83-90. doi: 10.1093/infdis/jiab374. 2022.
Zhang S, Liu F, Halfmann P, Behrens RT, Liu P, Mcilwain SJ, Ong IM, Donahue K, Wang Y, Kawaoka Y, Sherer N, Xu W. Mediator complex subunit 12 is a gatekeeper of SARS-CoV-2 infection in breast cancer cells. Genes Dis 9(1):5-8, 2022.
Hatakeyama D, Shoji M, Ogata S, Masuda T, Nakano M, Komatsu T, Saitoh A, Makiyama K, Tsuneishi H, Miyatake A, Takahira M, Nishikawa E, Ohkubo A, Noda T, Kawaoka Y, Ohtsuki S, Kuzuhara T. Acetylation of the influenza A virus polymerase subunit PA in the N-terminal domain positively regulates its endonuclease activity. FEBS J 293(19):7126-7138, 2022.
Eiden J, Gordon G, Fierro C, Herber R, Aitchison R, Belshe R, Greenberg H, Hoft D, Hatta Y, Moser MJ, Tary-Lehmann M, Kawaoka Y, Neumann G, Radspinner P, Bilsel P. Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults. Vaccines (Basel). 9(12):1388, 2021.
Urano E, Okamura T, Ono C, Ueno S, Nagata S, Kamada H, Higuchi M, Furukawa M, Kamitani W, Matsuura Y, Kawaoka Y, Yasutomi Y. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proc Natl Acad Sci U S A 118(43):e2104847118, 2021.
Yamaguchi T, Hoshizaki M, Minato T, Nirasawa S, Asaka MN, Niiyama M, Imai M, Uda A, Chan JF, Takahashi S, An J, Saku A, Nukiwa R, Utsumi D, Kiso M, Yasuhara A, Poon VK, Chan CC, Fujino Y, Motoyama S, Nagata S, Penninger JM, Kamada H, Yuen KY, Kamitani W, Maeda K, Kawaoka Y, Yasutomi Y, Imai Y, Kuba K. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. Nat Commun 12(1):6791, 2021.
Asaka MN, Utsumi D, Kamada H, Nagata S, Nakachi Y, Yamaguchi T, Kawaoka Y, Kuba K, Yasutomi Y. Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2 transgenic mice. JCI Insight 6(19):e152529, 2021.
Amjadi MF, O'Connell SE, Armbrust T, Mergaert AM, Narpala SR, Halfmann PJ, Bashar SJ, Glover CR, Heffron AS, Taylor A, Flach B, O'Connor DH, Kawaoka Y, McDermott AB, Sethi AK, Shelef MA. Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. Immunohorizons 5(6):466-476, 2021.
Orimoto A, Takahashi K, Imai M, Kiyono T, Kawaoka Y, Fukuda T. Establishment of human airway epithelial cells with doxycycline-inducible cell growth and fluorescence reporters. Cytotechnology 73(4):555-569, 2021.
Heffron AS, McIlwain SJ, Amjadi MF, Baker DA, Khullar S, Armbrust T, Halfmann PJ, Kawaoka Y, Sethi AK, Palmenberg AC, Shelef MA, O'Connor DH, Ong IM. The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biol 19(6):e3001265, 2021.
Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A 118(27):e2106535118, 2021.
Feng S, Heath E, Jefferson B, Joslyn C, Kvinge H, Mitchell HD, Praggastis B, Eisfeld AJ, Sims AC, Thackray LB, Fan S, Walters KB, Halfmann PJ, Westhoff-Smith D, Tan Q, Menachery VD, Sheahan TP, Cockrell AS, Kocher JF, Stratton KG, Heller NC, Bramer LM, Diamond MS, Baric RS, Waters KM, Kawaoka Y, McDermott JE, Purvine E. Hypergraph models of biological networks to identify genes critical to pathogenic viral response. BMC Bioinformatics 22(1):287, 2021.
Dugan HL, Stamper CT, Li L, Changrob S, Asby NW, Halfmann PJ, Zheng NY, Huang M, Shaw DG, Cobb MS, Erickson SA, Guthmiller JJ, Stovicek O, Wang J, Winkler ES, Madariaga ML, Shanmugarajah K, Jansen MO, Amanat F, Stewart I, Utset HA, Huang J, Nelson CA, Dai YN, Hall PD, Jedrzejczak RP, Joachimiak A, Krammer F, Diamond MS, Fremont DH, Kawaoka Y, Wilson PC. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54(6):1290-1303.e7, 2021.
Lee W, Kingstad-Bakke B, Kedl RM, Kawaoka Y, Suresh M. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus. J Virol 95(15):e0053021, 2021.
Chiba S, Frey SJ, Halfmann PJ, Kuroda M, Maemura T, Yang JE, Wright ER, Kawaoka Y, Kane RS. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Commun Biol 4(1):597, 2021.
Saito M, Itoh Y, Yasui F, Munakata T, Yamane D, Ozawa M, Ito R, Katoh T, Ishigaki H, Nakayama M, Shichinohe S, Yamaji K, Yamamoto N, Ikejiri A, Honda T, Sanada T, Sakoda Y, Kida H, Le TQM, Kawaoka Y, Ogasawara K, Tsukiyama-Kohara K, Suga H, Kohara M. Macrocyclic peptides exhibit antiviral effects against influenza virus HA and prevent pneumonia in animal models. Nat Commun 12(1):2654, 2021.
Nemoto M, Ohta M, Yamanaka T, Kambayashi Y, Bannai H, Tsujimura K, Yamayoshi S, Kawaoka Y, Cullinane A. Antigenic differences between equine influenza virus vaccine strains and Florida sublineage clade 1 strains isolated in Europe in 2019. Vet J 272:105674. doi: 10.1016/j.tvjl.2021.105674. Epub 2021 Apr 14.
Uwamino Y, Nagata M, Aoki W, Nakagawa T, Inose R, Yokota H, Furusawa Y, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hasegawa N, Murata M; Keio Donner Project Members. Accuracy of rapid antigen detection test for nasopharyngeal swab specimens and saliva samples in comparison with RT-PCR and viral culture for SARS-CoV-2 detection. J Infect Chemother S1341-321X(21)00117-3, 2021.
Gunn BM, Lu R, Slein MD, Ilinykh PA, Huang K, Atyeo C, Schendel SL, Kim J, Cain C, Roy V, Suscovich TJ, Takada A, Halfmann PJ, Kawaoka Y, Pauthner MG, Momoh M, Goba A, Kanneh L, Andersen KG, Schieffelin JS, Grant D, Garry RF, Saphire EO, Bukreyev A, Alter G. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity 54(4):815-828.e5, 2021.
Kingstad-Bakke B, Toy R, Lee W, Pradhan P, Vogel G, Marinaik CB, Larsen A, Gates D, Luu T, Pandey B, Kawaoka Y, Roy K, Suresh M. Polymeric Pathogen-Like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus. Front Immunol 11:559382, 2021.
Takashita E, Kawakami C, Momoki T, Saikusa M, Shimizu K, Ozawa H, Kumazaki M, Usuku S, Tanaka N, Okubo I, Morita H, Nagata S, Watanabe S, Hasegawa H, Kawaoka Y. Increased risk of rhinovirus infection in children during the coronavirus disease-19 pandemic. Influenza Other Respir Viruses 15(4):488-494, 2021.
Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, Koga M, Adachi E, Saito M, Nakachi I, Ogura T, Baba R, Ito M, Kiso M, Yasuhara A, Yamada S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Yamayoshi S, Yotsuyanagi H, Kawaoka Y, Khurana S. Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. Sci Adv 7(10):eabf2467, 2021.
Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine 32:100734, 2021.
Braun KM, Moreno GK, Halfmann PJ, Hodcroft EB, Baker DA, Boehm EC, Weiler AM, Haj AK, Hatta M, Chiba S, Maemura T, Kawaoka Y, Koelle K, O'Connor DH, Friedrich TC. Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. PLoS Pathog 17(2):e1009373, 2021.
Kong H, Burke DF, da Silva Lopes TJ, Takada K, Imai M, Zhong G, Hatta M, Fan S, Chiba S, Smith D, Neumann G, Kawaoka Y. Plasticity of the Influenza Virus H5 HA Protein. mBio 12(1):e03324-20, 2021.
Ohta M, Bannai H, Kambayashi Y, Tamura N, Tsujimura K, Yamayoshi S, Kawaoka Y, Nemoto M. Growth properties and immunogenicity of a virus generated by reverse genetics for an inactivated equine influenza vaccine. Equine Vet J. 54:139-144, 2022.
Chiba S, Halfmann PJ, Hatta M, Maemura T, Fan S, Armbrust T, Swartley OM, Crawford LK, Kawaoka Y. Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 Infection. Emerg Infect Dis 27(2):660-663, 2021.
Guthmiller JJ, Stovicek O, Wang J, Changrob S, Li L, Halfmann P, Zheng NY, Utset H, Stamper CT, Dugan HL, Miller WD, Huang M, Dai YN, Nelson CA, Hall PD, Jansen M, Shanmugarajah K, Donington JS, Krammer F, Fremont DH, Joachimiak A, Kawaoka Y, Tesic V, Madariaga ML, Wilson PC. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. mBio 12(1):e02940-20, 2021.
Alzhanova D, Corcoran K, Bailey AG, Long K, Taft-Benz S, Graham RL, Broussard GS, Heise M, Neumann G, Halfmann P, Kawaoka Y, Baric RS, Damania B, Dittmer DP. Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. PLoS Pathog 17(1):e1009033, 2021.

2020

Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Omagari N, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Comparison of Rapid Antigen Tests for COVID-19. Viruses 12(12):1420, 2020.
Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH 3rd, Leist SR, Schäfer A, Nakajima N, Takahashi K, Lee RE, Mascenik TM, Graham R, Edwards CE, Tse LV, Okuda K, Markmann AJ, Bartelt L, de Silva A, Margolis DM, Boucher RC, Randell SH, Suzuki T, Gralinski LE, Kawaoka Y, Baric RS. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370(6523):1464-1468, 2020.
Moreno GK, Braun KM, Riemersma KK, Martin MA, Halfmann PJ, Crooks CM, Prall T, Baker D, Baczenas JJ, Heffron AS, Ramuta M, Khubbar M, Weiler AM, Accola MA, Rehrauer WM, O'Connor SL, Safdar N, Pepperell CS, Dasu T, Bhattacharyya S, Kawaoka Y, Koelle K, O'Connor DH, Friedrich TC. Revealing fine-scale spatiotemporal differences in SARS-CoV-2 introduction and spread. Nat Commun 11:5558, 2020.
Ueki H, Furusawa Y, Iwatsuki-Horimoto K, Imai M, Kabata H, Nishimura H, Kawaoka Y. Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2. mSphere. 5:e00637-20, 2020.
Kuroda M, Halfmann P, Kawaoka Y. HER2-mediated enhancement of Ebola virus entry. PLoS Pathog 16:e1008900, 2020.
Marinaik CB, Kingstad-Bakke B, Lee W, Hatta M, Sonsalla M, Larsen A, Neldner B, Gasper DJ, Kedl RM, Kawaoka Y, Suresh M. Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants. Cell Rep Med 1:100095, 2020.
Westmark CJ, Kiso M, Halfmann P, Westmark PR, Kawaoka Y. Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction. Front Cell Dev Biol 8:856, 2020.
Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Shiraki T, Uchida S, Uno S, Kabata H, Ikemura S, Kamata H, Ishii M, Fukunaga K, Kawaoka Y, Hasegawa N, Murata M. Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol 74(1):67-68, 2021.
Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, Yasuhara A, Sakai-Tagawa Y, Lopes TJS, Kiso M, Yamayoshi S, Kinoshita N, Ohmagari N, Hattori SI, Takeda M, Mitsuya H, Krammer F, Suzuki T, Kawaoka Y. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci USA 117(28):16587-16595, 2020.
Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner. Viruses 12(6):629, 2020.
Kuroda M, Halfmann PJ, Hill-Batorski L, Ozawa M, Lopes TJS, Neumann G, Schoggins JW, Rice CM, Kawaoka Y. Identification of interferon-stimulated genes that attenuate Ebola virus infection. Nat Commun 11(1):2953, 2020.
Fukuyama S, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Gregg RW, Katsura H, Tomita Y, Maemura T, da Silva Lopes TJ, Watanabe T, Shoemaker JE, Hasegawa H, Yamayoshi S, Kawaoka Y. Pathogenesis of Influenza A(H7N9) Virus in Aged Nonhuman Primates. J Infect Dis 222(7):1155-1164, 2020.
Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori SI, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med 383(6):592-594, 2020.
Feng H, Nakatsu S, Lopes TJDS, Imai M, Yamayoshi S, Yamashita M, Watanabe T, Kawaoka Y. Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine. Vaccines (Basel) 8: E215, 2020.
Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Commun Biol 3(1):219, 2020.
Azekawa S, Namkoong H, Mitamura K, Kawaoka Y, Saito F. Co-infection with SARS-CoV-2 and influenza A virus. IDCases 20:e00775, 2020.
Martinez-Sobrido L, Blanco-Lobo P, Rodriguez L, Fitzgerald T, Zhang H, Nguyen P, Anderson CS, Holden-Wiltse J, Bandyopadhyay S, Nogales A, DeDiego ML, Wasik BR, Miller BL, Henry C, Wilson PC, Sangster MY, Treanor JJ, Topham DJ, Byrd-Leotis L, Steinhauer DA, Cummings RD, Luczo JM, Tompkins SM, Sakamoto K, Jones CA, Steel J, Lowen AC, Danzy S, Tao H, Fink AL, Klein SL, Wohlgemuth N, Fenstermacher KJ, El Najjar F, Pekosz A, Sauer L, Lewis MK, Shaw-Saliba K, Rothman RE, Liu ZY, Chen KF, Parrish CR, Voorhees IEH, Kawaoka Y, Neumann G, Chiba S, Fan S, Hatta M, Kong H, Zhong G, Wang G, Uccellini MB, García-Sastre A, Perez DR, Ferreri LM, Herfst S, Richard M, Fouchier R, Burke D, Pattinson D, Smith DJ, Meliopoulos V, Freiden P, Livingston B, Sharp B, Cherry S, Dib JC, Yang G, Russell CJ, Barman S, Webby RJ, Krauss S, Danner A, Woodard K, Peiris M, Perera RAPM, Chan MCW, Govorkova EA, Marathe BM, Pascua PNQ, Smith G, Li YT, Thomas PG, Schultz-Cherry S. Characterizing Emerging Canine H3 Influenza Viruses. PLoS Pathog 16:e1008409, 2020.
Saito M, Adachi E, Yamayoshi S, Koga M, Iwatsuki-Horimoto K, Kawaoka Y, Yotsuyanagi H. Gargle lavage as a safe and sensitive alternative to swab samples to diagnose COVID-19: a case report in Japan. Clin Infect Dis 71:893-894, 2020.
Maemura T, Fukuyama S, Kawaoka Y. High Levels of miR-483-3p Are Present in Serum Exosomes Upon Infection of Mice With Highly Pathogenic Avian Influenza Virus. Front Microbiol 11:144, 2020.
Mitake H, Yasuhara A, Lopes TJS, Tagawa-Sakai Y, Shimizu K, Ozawa H, Kawakami C, Morikawa S, Sugaya N, Watanabe T, Kawaoka Y. Comparison of the Pathogenicity in Mice of A(H1N1)pdm09 Viruses Isolated between 2009 and 2015 in Japan. Viruses 12(2). pii: E155, 2020.
Ueki H, Wang IH, Zhao D, Gunzer M, Kawaoka Y. Multicolor two-photon imaging of in vivo cellular pathophysiology upon influenza virus infection using the two-photon IMPRESS. Nat Protoc 15:1041-1065, 2020.
Kato-Miyashita, S, Sakai-Tagawa Y, Yamashita M, Iwatsuki-Horimoto K, Ito M, Tokita A, Hagiwara H, Izumida N, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Yotsuyanagi H, kawaoka Y, Imai M. Antigenic variants of influenza B viruses isolated in Japan during the 2017‐2018 and 2018‐2019 influenza seasons. Influenza Other Respi Viruses 14:311-319, 2020.
Furuyama W, Reynolds P, Haddock E, Meade-White K, Le MQ, Kawaoka Y, Feldmann H, Marzi A. A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades. NPJ Vaccines 5:4, 2020.
Wang M, Fukuyama S, Kawaoka Y, Shoemaker JE. Predicting Host Immune Cell Dynamics and Key Disease-Associated Genes Using Tissue Transcriptional Profiles. Processes 7:301, 2019.
Kuwahara T, Yamayoshi S, Noda T, Kawaoka Y. G Protein Pathway Suppressor 1 Promotes Influenza Virus Polymerase Activity by Activating the NF-κB Signaling Pathway. mBio 10:e02867-19, 2019.
Kiso M, Yamayoshi S, Murakami J, Kawaoka Y. Baloxavir marboxil treatment of nude mice infected with influenza A virus. J Infect Dis 221:1699-1702, 2020.
Zhong G, Fan S, Hatta M, Nakatsu S, Walters KB, Lopes TJS, Wang JI, Ozawa M, Karasin A, Li Y, Tong S, Donis RO, Neumann G, Kawaoka Y. Mutations in the NA-like protein of bat influenza H18N11 virus enhance virus replication in mammalian cells, mice, and ferrets. J Virol 94:e01416-19, 2020.
Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat Microbiol 5:27-33, 2020.

2019

Kiso M, Yamayoshi S, Furusawa Y, Imai M, Kawaoka Y. Treatment of highly pathogenic H7N9 virus-infected mice with baloxavir marboxil. Viruses 11(11). pii: E1066, 2019.
Sakai-Tagawa Y, Yamayoshi S, Kawaoka Y. Sensitivity of commercially available influenza rapid diagnostic tests in the 2018-2019 influenza season. Front Microbiol 10:2342, 2019.
Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, Okuda M, Go Y, Watanabe T, Imai M, Arai Y, Fouchier RAM, Yamayoshi S, Kawaoka Y. Antigenic change in human influenza A(H2N2) viruses detected by using human plasma from aged and younger adult individuals. Viruses 11(11). pii: E978, 2019.
Wu L, Mitake H, Kiso M, Ito M, Iwatsuki-Hirimoto K, Yamayoshi S, Lopes TJS, Feng H, Sumiyoshi R, Shibata A, Osaka H, Imai M, Watanabe T, Kawaoka Y. Characterization of H7N9 avian influenza viruses isolated from duck meat products. Transbound Emerg Dis 00:1-7, 2019.
Feldmann F, Kobasa D, Embury-Hyatt C, Grolla A, Taylor T, Kiso M, Kakugawa S, Gren J, Jones SM, Kawaoka Y, Feldmann H. Oseltamivir is effective against 1918 influenza virus infection of macaques but vulnerable to escape. mBio 10(5). pii: e02059-19, 2019.
Feng H, Nakajima N, Wu L, Yamashita M, Lopes TJS, Tsuji M, Hasegawa H, Watanabe T, Kawaoka Y. A Glycolipid adjuvant, 7DW8-5, enhances the protective immune response to the current split influenza vaccine in mice. Front Microbio 10:2157, 2019.
Mitchell HD, Eisfeld AJ, Stratton KG, Heller NC, Bramer LM, Wen J, McDermott JE, Gralinski LE, Sims AC, Le MQ, Baric RS, Kawaoka Y, Waters KM. The role of EGFR in influenza pathogenicity: multiple network-based approaches to identify a key regulator of non-lethal infections. Front Cell Dev Biol 7:200, 2019.
Furusawa Y, Yamada S, da Silva Lopes TJ, Dutta J, Khan Z, Kriti D, van Bakel H, Kawaoka Y. Influenza virus polymerase mutation stabilizes a foreign gene inserted into the virus genome by enhancing the transcription/replication efficiency of the modified segment. mBio 10(5). pii:e01794-19, 2019.
Feng H, Yamashita M, Wu L, Jose da Silva Lopes T, Watanabe T, Kawaoka Y. Food additives as novel Influenza vaccine adjuvants. Vaccines (Basel) 7(4). pii: E127, 2019.
Yamada S, Yasuhara A, Kawaoka Y. Soluble recombinant hemagglutinin protein of H1N1pdm09 influenza viruse elicits cross-protection against a lethal H5N1 challenge in mice. Front Microbiol 10:2031, 2019.
Mukai Y, Tomita Y, Kryukov K, Nakagawa S, Ozawa M, Matsui T, Tomonaga K, Imanishi T, Kawaoka Y, Watanabe T, Horie M. Identification of a distinct lineage of aviadenovirus from crane feces. Virus Genes 55:815-824, 2019
Ujie M, Takada K, Kiso M, Sakai-Tagawa Y, Ito M, Nakamura K, Watanabe S, Imai M, Kawaoka Y. Long-term culture of human lung adenocarcinoma A549 cells enhances the replication of human influenza A viruses. J Gen Virol 100:1345-1349, 2019.
Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, Le MQ, Kawaoka Y, Ogasawara K, Shimizu T. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res 171:104591, 2019.
DiPiazza AT, Fan S, Rattan A, DeDiego ML, Chaves F, Neumann G, Kawaoka Y, Sant AJ. A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza. J Immunol 203(6):1502-1508, 2019.
Halfmann PJ, Eisfeld AJ, Watanabe T, Maemura T, Yamashita M, Fukuyama S, Armbrust T, Rozich I, N'jai A, Neumann G, Kawaoka Y, Sahr F. Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study. PLoS Negl Trop Dis. 13(8):e0007654, 2019.
Kingstad-Bakke BA, Chandrasekar SS, Phanse Y, Ross KA, Hatta M, Suresh M, Kawaoka Y, Osorio JE, Narasimhan B, Talaat AM. Effective mosaic-based nanovaccines against avian influenza in poultry. Vaccine 37:5051-5058, 2019.
Moser MJ, Hatta Y, Gabaglia C, Sanchez A, Dias P, Sarawar S, Kawaoka Y, Hatta M, Neumann G, Bilsel P. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice. Vaccine 37:4533-4542, 2019.
Nemoto M, Yamayoshi S, Bannai H, Tsujimura K, Kokado H, Kawaoka Y, Yamanaka T. A single amino acid change in hemagglutinin reduces the cross-reactivity of antiserum against an equine influenza vaccine strain. Arch Virol 164:2355-2358, 2019.
Zhong G, Fan S, Lopes TJS, Le MQ, van Bakel H, Dutta J, Smith GJD, Jayakumar J, Nguyen HLK, Hoang PVM, Halfmann P, Hatta M, Su YCF, Neumann G, Kawaoka Y. Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009-2013 in Vietnam. Front Microbiol 10:1411, 2019.
Liang L, Jiang L, Li J, Zhao Q, Wang J, He X, Huang S, Wang Q, Zhao Y, Wang G, Sun N, Deng G, Shi J, Tian G, Zeng X, Jiang Y, Liu L, Liu J, Chen P, Bu Z, Kawaoka Y, Chen H, Li C. Low Polymerase Activity Attributed to PA Drives the Acquisition of the PB2 E627K Mutation of H7N9 Avian Influenza Virus in Mammals. mBio 10:e01162-19, 2019.
Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R. Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. Cell 177:1566-1582, 2019.
Okuda M, Yamayoshi S, Uraki R, Ito M, Hamabata T, Kawaoka Y. Subclade 2.2.1-Specific Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018. Viruses 11:E321, 2019.
Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, Shimizu K, Takasaki S, Sakai-Tagawa Y, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Yamada S, Watanabe T, Imai M, Kawaoka Y. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Nat Microbiol 4:1268-1273, 2019.
Oishi K, Yamayoshi S, Kawaoka Y. Identification of Amino Acid Residues in Influenza A Virus PA-X That Contribute to Enhanced Shutoff Activity. Front Microbiol 10:432, 2019.
Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Koga M, Adachi E, Kikuchi T, Wang IH, Yamada S, Kawaoka Y. Antigenic drift originating from changes to the lateral surface of the neuraminidase head of influenza A virus. Nat Microbiol 4:1024-1034, 2019.
Kyle JE, Burnum-Johnson KE, Wendler JP, Eisfeld AJ, Halfmann PJ, Watanabe T, Sahr F, Smith RD, Kawaoka Y, Waters KM, Metz TO. Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. Proc Natl Acad Sci U S A. 116:3919-3928, 2019.
Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H, Fujisaki S, Pattinson DJ, Shimizu K, Ozawa H, Momoki T, Saikusa M, Yasuhara A, Usuku S, Okubo I, Toyozawa T, Sugita S, Smith DJ, Watanabe S, Kawaoka Y. Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro Surveill 24:1800467, 2019.
Ito M, Yamayoshi S, Murakami K, Saito K, Motojima A, Nakaishi K, Kawaoka Y. Viruses. Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus. Viruses 11:E149, 2019.
Feng H, Yamashita M, da Silva Lopes TJ, Watanabe T, Kawaoka Y. Injectable Excipients as Novel Influenza Vaccine Adjuvants. Front Microbiol 10:19, 2019.
Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. J Virol 93:e01439-18, 2019.
Tabata KV, Minagawa Y, Kawaguchi Y, Ono M, Moriizumi Y, Yamayoshi S, Fujioka Y, Ohba Y, Kawaoka Y, Noji H. Antibody-free digital influenza virus counting based on neuraminidase activity. Sci Rep 9:1067, 2019.
Eisfeld AJ, Gasper DJ, Suresh M, KawaokaY. C57BL/6J and C57BL/6NJ Mice Are Differentially Susceptible to Inflammation-Associated Disease Caused by Influenza A Virus. Front Microbiol 9:3307, 2019.
Gu C, Zeng X, Song Y, Li Y, Liu L, Kawaoka Y, Zhao D, Chen H. Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses. Sci China Life Sci 62:76-83, 2019.

2018

Ackerman EE, Kawakami E, Katoh M, Watanabe T, Watanabe S, Tomita Y, Lopes TJ, Matsuoka Y, Kitano H, Shoemaker JE, Kawaoka Y. Network-Guided Discovery of Influenza Virus Replication Host Factors. mBio. 9: e02002-18, 2018.
Yasuhara A, Yamayoshi S, Ito M, Kiso M, Yamada S, Kawaoka Y. Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses. Front Microbiol 9:2660, 2018.
Bedi S, Noda T, Kawaoka Y, Ono A. A Defect in Influenza A Virus Particle Assembly Specific to Primary Human Macrophages. mBio:9:e01916-18, 2018.
Sugita Y, Matsunami H, Kawaoka Y, Noda T, Wolf M. Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex at 3.6 Å resolution. Nature 563:137-140, 2018.
Wu NC, Yamayoshi S, Ito M, Uraki R, Kawaoka Y, Wilson IA. Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. Cell Host Microbe 24:569-578, 2018.
Yamayoshi S, Yasuhara A, Ito M, Uraki R, Kawaoka Y. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. J Clin Virol 108:105-111, 2018.
Chiba S, Hill-Batorski L, Neumann G, Kawaoka Y. The Cellular DExD/H-Box RNA Helicase UAP56 Co-localizes With the Influenza A Virus NS1 Protein. Front Microbiol 9:2192, 2018.
Hatta M, Zhong G, Chiba S, Lopes TJS, Neumann G, Kawaoka Y. Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus. Emerg Infect Dis 24:1910-1913,2018.
Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell 174:938-952, 2018.
Gunn BM, Yu WH, Karim MM, Brannan JM, Herbert AS, Wec AZ, Halfmann PJ, Fusco ML, Schendel SL, Gangavarapu K, Krause T, Qiu X, He S, Das J, Suscovich TJ, Lai J, Chandran K, Zeitlin L, Crowe JE Jr, Lauffenburger D, Kawaoka Y, Kobinger GP, Andersen KG, Dye JM, Saphire EO, Alter G. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host Microbe 24:221-233, 2018.
Furusawa Y, Yamada S, Kawaoka Y. Host Factor Nucleoporin 93 Is Involved in the Nuclear Export of Influenza Virus RNA. Front Microbiol 9:1675, 2018.
Halfmann P, Hill-Batorski L, Kawaoka Y. The Induction of IL-1β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection. J Infect Dis 218(suppl_5):S504-S507, 2018.
Oishi K, Yamayoshi S, Kozuka-Hata H, Oyama M, Kawaoka Y. N-terminal acetylation by NatB is required for the shutoff activity of influenza A virus PA-X. Cell Rep 24(4):851-860, 2018.
Sammaibashi S, Yamayoshi S, Kawaoka Y. Strain-specific contribution of eukaryotic elongation factor 1 gamma to the translation of influenza A virus proteins. Front Microbiol 9:1446, 2018.
Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. Vaccine 36:5097-5103, 2018.
Iwatsuki-Horimoto K, Shi J, Wang X, Sakai-Tagawa Y, Ito M, Murakami K, da Silva Lopes TJ, Nakaishi K, Yamayoshi S, Watabe S, Chen H, Kawaoka Y. Development of an influenza rapid diagnostic kit specific for the H7 subtype. Front Microbiol 9:1346, 2018.
Ueki H, Wang IH, Fukuyama S, Katsura H, da Silva Lopes TJ, Neumann G, Kawaoka Y. In vivo imaging of the pathophysiological changes and neutrophil dynamics in influenza virus-infected mouse lungs. Proc Natl Acad Sci U S A 115:E6622-E6629, 2018.
Imai H, Dinis JM, Zhong G, Moncla LH, Lopes TJS, McBride R, Thompson AJ, Peng W, Le MTQ, Hanson A, Lauck M, Sakai-Tagawa Y, Yamada S, Eggenberger J, O'Connor DH, Suzuki Y, Hatta M, Paulson JC, Neumann G, Friedrich TC, Kawaoka Y. Diversity of influenza A(H5N1) Vvruses in infected humans, Northern Vietnam, 2004-2010. Emerg Infect Dis 24:1128-1238, 2018.
Iwatsuki-Horimoto K, Nakajima N, Kiso M, Takahashi K, Ito M, Inoue T, Horiuchi M, Okahara N, Sasaki E, Hasegawa H, Kawaoka Y. The marmoset as an animal model of influenza: infection with A(H1N1)pdm09 and highly pathogenic A(H5N1) viruses via the conventional or tracheal spray route. Front Microbiol 9:844, 2018.
Kuwahara T, Takashita E, Fujisaki S, Shirakura M, Nakamura K, Kishida N, Takahashi H, Suzuki N, Kawaoka Y, Watanabe S, Odagiri T. Isolation of egg-adapted influenza A(H3N2) virus without amino acid substitutions in the antigenic sites of its hemagglutinin. Jpn J Infect Dis 71:234-238, 2018.
Soni P, Yasuhara A, Takenaga T, Iwatsuki-Horimoto K, Uraki R, Ito M, Sasaki T, Ikuta K, Yamayoshi S, Kawaoka Y. Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus. J Vet Med Sci 80:1020-1024, 2018.
Fujihira H, Usami K, Matsuno K, Takeuchi H, Denda-Nagai K, Furukawa JI, Shinohara Y, Takada A, Kawaoka Y, Irimura T. A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity. Sci Rep 8:5495, 2018.
Hatakeyama D, Shoji M, Yamayoshi S, Yoh R, Ohmi N, Takenaka S, Saitoh A, Arakaki Y, Masuda A, Komatsu T, Nagano R, Nakano M, Noda T, Kawaoka Y, Kuzuhara T. Influenza A virus nucleoprotein is acetylated by histone acetyltransferases, PCAF and GCN5. J Biol Chem293:7126-7138, 2018.
Matsui K, Ozawa M, Kiso M, Yamashita M, Maekawa T, Kubota M, Sugano S, Kawaoka Y. Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. Sci Rep 8:4631, 2018.
Watanabe T, Iwatsuki-Horimoto K, Kiso M, Nakajima N, Takahashi K, Lops TJS, Ito M, Fukuyama S, Hasegawa H, kawaoka Y. Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route. Sci Rep 8:4801, 2018.
Yamayoshi S, Kiso M, Yasuhara A, Ito M, Shu Y, Kawaoka Y. Identification of amino acids that enhance replication in mammalian hosts in the PB2 and PA proteins of a highly pathogenic H7N9 influenza virus isolated from a human. Emerg Infect Dis 24:746-750, 2018.
Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, Nicora CD, Purvine SO, Casey CP, Monroe ME, Weitz KK, Stratton KG, Webb-Robertson BM, Gralinski LE, Metz TO, Smith RD, Waters KM, Sims AC, Kawaoka Y, Baric RS. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci USA 115:E1012-E1021, 2018.
Maemura T, Fukuyama S, Sugita Y, Lopes TJS, Nakao T, Noda T, Kawaoka Y. Lung-derived exosomal miR-483-3p regulates the innate immune response to influenza virus infection. J Infect Dis 217:1372-1382, 2018.
Nanbo A, Maruyama J, Imai M, Ujie M, Fujioka Y, Nishide S, Takada A, Ohba Y, Kawaoka Y. Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles. PLoS Pathog 14:e1006848, 2018.
Yamayoshi S, Ito M, Uraki R, Sasaki T, Ikuta K, Kawaoka Y. Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from H3N2 virus-infected humans. J Infect 76:177-185, 2018.
Noda T, Murakami S, Nakatsu S, Imai H, Muramoto Y, Shindo K, Sagara H, Kawaoka Y. Importance of the 1+7 configuration of ribonucleoprotein complexes for influenza A virus genome packaging. Nat Commun 9:54, 2018.
Nakatsu S, Murakami S, Shindo K, Horimoto T, Sagara H, Noda T, Kawaoka Y. Influenza C and D viruses package eight organized ribonucleoprotein complexes. J Virol 92:e02084-17, 2018.
Oishi K, Yamayoshi S, Kawaoka Y. Identification of novel amino acid residues of influenza virus PA-X that are important for PA-X shutoff activity by using yeast. Virology 516:71-75, 2018.
Zhong G, Le MQ, Lopes TJS, Halfmann P, Hatta M, Fan S, Neumann G, Kawaoka Y. Mutations in the PA Protein of Avian H5N1 Influenza Viruses Affect Polymerase Activity and Mouse Virulence. J Virol 92:e01557-17, 2018.
Iwatsuki-Horimoto K, Nakajima N, Ichiko Y, Sakai-Tagawa Y, Noda T, Hasegawa H, Kawaoka Y. Syrian hamster as an animal model for the study of human influenza virus infection. J Virol 92:e01693-17, 2018.
Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y. Combination Therapy with Neuraminidase and Polymerase Inhibitors in Nude Mice Infected with Influenza Virus. J Infect Dis 217:887-896, 2018.
Hatta M, Zhong G, Gao Y, Nakajima N, Fan S, Chiba S, Deering KM, Ito M, Imai M, Kiso M, Nakatsu S, Lopes TJ, Thompson AJ, McBride R, Suarez DL, Macken CA, Sugita S, Neumann G, Hasegawa H, Paulson JC, Toohey-Kurth KL, Kawaoka Y. Characterization of a Feline Influenza A(H7N2) Virus. Emerg Infect Dis 24:75-86, 2018.

2017

Yasuhara A, Yamayoshi S, Soni P, Takenaga T, Kawakami C, Takashita E, Sakai-Tagawa Y, Uraki R, Ito M, Iwatsuki-Horimoto K, Sasaki T, Ikuta K, Yamada S, Kawaoka Y. Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. Sci Rep 7:17735, 2017.
Sakai-Tagawa Y, Yamayoshi S, Kawakami C, Le MQ, Uchida Y, Saito T, Nidom CA, Humaira I, Toohey-Kurth K, Arafa AS, Liu MT, Shu Y, Kawaoka Y. Reactivity and sensitivity of commercially available influenza rapid diagnostic tests in Japan. Sci Rep 7:14483, 2017.
Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. J Infect Dis 216:582-593, 2017.
Eisfeld AJ, Halfmann PJ, Wendler JP, Kyle JE, Burnum-Johnson KE, Peralta Z, Maemura T, Walters KB, Watanabe T, Fukuyama S, Yamashita M, Jacobs JM, Kim Y-M, Casey CP, Stratton KG, Webb-Robertson B-J, Gritsenko MA, Monroe ME, Weitz KK, Shukla AK, Tian M, Neumann G, Reed JL, van Bakel H, Metz TO, Smith RD, Waters KM, N’jai A, Sahr F, Kawaoka Y. Multi-Platform ‘Omics Analysis of human Ebola virus disease pathogenesis. Cell Host&Microbe 22:817-829, 2017.
Imai M, Watanabe T, Kiso M, Nakajima N, Yamayoshi S, Iwatsuki-Horimoto K, Hatta M, Yamada S, Ito M, Sakai-Tagawa Y, Shirakura M, Takashita E, Fujisaki S, McBride R, Thompson AJ, Takahashi K, Maemura T, Mitake H, Chiba S, Zhong G, Fan S, Oishi K, Yasuhara A, Takada K, Nakao T, Fukuyama S, Yamashita M, Lopes TJS, Neumann G, Odagiri T, Watanabe S, Paulson JC, Hasegawa H, Kawaoka Y. Characterization of a highly pathogenic avian H7N9 influenza virus isolated from an infected human. Cell Host&Microbe 22:615-626, 2017.
Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza. Vaccine 35:4177-4183, 2017.
Yamayoshi S, Uraki R, Ito M, Kiso M, Nakatsu S, Yasuhara A, Oishi K, Sasaki T, Ikuta K, Kawaoka Y. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus EBioMedicine 17:182-191, 2017.
Ui H, Yamayoshi S, Uraki R, Kiso M, Oishi K, Murakami S, Mimori S, Kawaoka Y. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine 35:1892-1897, 2017.
Nakayama M, Itoh Y, Shichinohe S, Nakabayashi R, Ishigaki H, Sakoda Y, Le QM, Kawaoka Y, Kida H, Ogasawara K. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus. Vaccine 35:1008-1017, 2017.
Zhao D, Liang L, Wang S, Nakao T, Li Y, Liu L, Guan Y, Fukuyama S, Bu Z, Kawaoka Y, Chen H. Glycosylation of the HA protein of H5N1 virus increases its virulence in mice by exacerbating the host immune response. J Virol 91: e02215-02216, 2017.
Burnum-Johnson KE, Kyle JE, Eisfeld AJ, Casey CP, Stratton KG, Gonzalez JF, Habyarimana F, Negretti NM, Sims AC, Chauhan S, Thackray LB, Halfmann PJ, Walters KB, Kim YM, Zink EM, Nicora CD, Weitz KK, Webb-Robertson BM, Nakayasu ES, Ahmer B, Konkel ME, Motin V, Baric RS, Diamond MS, Kawaoka Y, Waters KM, Smith RD, Metz TO. MPLEx: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling. Analyst 142:442-448, 2017.
Iwatsuki-Horimoto K, Nakajima N, Shibata M, Takahashi K, Sato Y, Kiso M, Yamayoshi S, Ito M, Enya S, Otake M, Kangawa A, da Silva Lopes TJ, Ito H, Hasegawa H, Kawaoka Y. Microminipigs as an animal model for influenza A virus infection. J Virol 91:e01716,2017.

2016

Gasper DJ, Neldner B, Plisch EH, Rustom H, Carrow E, Imai H, Kawaoka Y, Suresh M. Effective respiratory CD8 T-cell immunity to influenza virus induced by intranasal carbomer-lecithin-adjuvanted non-replicating vaccines. PLoS Pathog. 12:e1006064, 2016.
Ping J, Lopes TJ, Neumann G, Kawaoka Y. Development of high-yield influenza B virus vaccine viruses. Proc Natl Acad Sci U S A. 113:E8296-E8305, 2016.
Arafa AS, Yamada S, Imai M, Watanabe T, Yamayoshi S, Iwatsuki-Horimoto K, Kiso M, Sakai-Tagawa Y, Ito M, Imamura T, Nakajima N, Takahashi K, Zhao D, Oishi K, Yasuhara A, Macken CA, Zhong G, Hanson AP, Fan S, Ping J, Hatta M, Lopes TJ, Suzuki Y, El-Husseiny M, Selim A, Hagag N, Soliman M, Neumann G, Hasegawa H, Kawaoka Y. Risk assessment of recent Egyptian H5N1 influenza viruses. Sci Rep. 6:38388, 2016.
Miyauchi K, Sugimoto-Ishige A, Harada Y, Adachi Y, Usami Y, Kaji T, Inoue K, Hasegawa H, Watanabe T, Hijikata A, Fukuyama S, Maemura T, Okada-Hatakeyama M, Ohara O, Kawaoka Y, Takahashi Y, Takemori T, Kubo M. Protective neutralizing influenza antibody response in the absence of T follicular helper cells. Nat Immunol 17:1447-1458,2016.
Sarawar S, Hatta Y, Watanabe S, Dias P, Neumann G, Kawaoka Y, Bilsel P. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice. Vaccine 34:5090-5098,2016.
Nakatsu S, Sagara H, Sakai-Tagawa Y, Sugaya N, Noda T, Kawaoka Y. Complete and Incomplete Genome Packaging of Influenza A and B Viruses. mBio 7:e01248-16, 2016.
Chasman D, Walters KB, Lopes TJ, Eisfeld AJ, Kawaoka Y, Roy S. Integrating Transcriptomic and Proteomic Data Using Predictive Regulatory Network Models of Host Response to Pathogens. PLoS Comput Biol 12:e1005013, 2016.
Takashita E, Ejima M, Ogawa R, Fujisaki S, Neumann G, Furuta Y, Kawaoka Y, Tashiro M, Odagiri T.Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res 132:170-177, 2016.
Westhoff Smith D, Hill-Batorski L, N'jai A, Eisfeld AJ, Neumann G, Halfmann P, Kawaoka Y. Ebola Virus Stability Under Hospital and Environmental Conditions. J Infect Dis 214:S142-S144,2016.
Hsin KY, Matsuoka Y, Asai Y, Kamiyoshi K, Watanabe T, Kawaoka Y, Kitano H. systemsDock: a web server for network pharmacology-based prediction and analysis. Nucleic Acids Res 44:W507-513, 2016.
Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov A, Kelso A, McCauley J, Wang D, Shu Y, OdagiriT, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1:16058, 2016.
Ando T, Yamayoshi S, Tomita Y, Watanabe S, Watanabe T, Kawaoka Y. The host protein CLUH participates in the subnuclear transport of influenza virus ribonucleoprotein complexes. Nat Microbiol 1:16062, 2016.
Tisoncik-Go J, Gasper DJ, Kyle JE, Eisfeld AJ, Selinger C, Hatta M, Morrison J, Korth MJ, Zink EM, Kim YM, Schepmoes AA, Nicora CD, Purvine SO, Weitz KK, Peng X, Green RR, Tilton SC, Webb-Robertson BJ, Waters KM, Metz TO, Smith RD, Kawaoka Y, Suresh M, Josset L, Katze MG. Integrated Omics Analysis of Pathogenic Host Responses during Pandemic H1N1 Influenza Virus Infection: The Crucial Role of Lipid Metabolism. Cell Host Microbe 19:254-266, 2016.
Moncla LH, Zhong G, Nelson CW, Dinis JM, Mutschler J, Hughes AL, Watanabe T, Kawaoka Y, Friedrich TC. Selective bottlenecks shape evolutionary pathways taken during mammalian adaptation of a 1918-like avian influenza virus. Cell Host Microbe 19:169-180, 2016.
Fujimoto Y, Ito H, Ono E, Kawaoka Y, Ito T. The low-pH resistance of neuraminidase is essential for the replication of influenza A virus in duck intestine following infection via the oral route. J Virol 90:4127-4132, 2016.
Katsura H, Fukuyama S, Watanabe S, Ozawa M, Neumann G, Kawaoka Y. Amino acid changes in PB2 and HA affect the growth of a recombinant influenza virus expressing a fluorescent reporter protein. Sci Rep 6:19933, 2016.
Niu Z, Chasman D, Eisfeld AJ, Kawaoka Y, Roy S. Multi-task consensus clustering of genome-wide transcriptomes from related biological conditions. Bioinformatics 32:1509-1517, 2016.
Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 90:3086-3092, 2016.
Yang H, Chen Y, Qiao C, He X, Zhou H, Sun Y, Yin H, Meng S, Liu L, Zhang Q, Kong H, Gu C, Li C, Bu Z, Kawaoka Y, Chen H. Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. Proc Natl Acad Sci USA 113:392-397, 2016.

2015

Hanson A, Imai M, Hatta M, McBride R, Imai H, Taft A, Zhong G, Watanabe T, Suzuki Y, Neumann G, Paulson JC, Kawaoka Y. Identification of stabilizing mutations in an H5 HA influenza virus protein. J Virol 90:2981-2992, 2015.
Zhao D, Fukuyama S, Sakai-Tagawa Y, Takashita E, Shoemaker JE, Kawaoka Y. C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, attenuates influenza A virus infection. Antimicrob Agents Chemother 60:1902-1906, 2015.
Forero A, Tisoncik-Go J, Watanabe T, Zhong G, Hatta M, Tchitchek N, Selinger C, Chang J, Barker K, Morrison J, Berndt JD, Moon RT, Josset L, Kawaoka Y, Katze MG. The 1918 PB2 protein enhances virulence through the disruption of inflammatory and Wnt-mediated signaling in mice. J Virol 90:2240-2253, 2015.
Oda SI, Noda T, Wijesinghe KJ, Halfmann P, Bornholdt ZA, Abelson DM, Armbrust T, Stahelin RV, Kawaoka Y, Saphire EO. Crystal structure of Marburg virus VP40: matrix assembly and immunosuppression. J Virol 90:1839-1848, 2015.
Yamayoshi S, Watanabe M, Goto H, Kawaoka Y. Identification of A novel viral protein expressed from the PB2 segment of influenza A virus. J Virol 90:444-456, 2015.
Lopes TJ, Shoemaker JE, Matsuoka Y, Kawaoka Y, Kitano H. Identifying problematic drugs based on the characteristics of their targets. Front Pharmacol.6:186, 2015.
Zhao D, Fukuyama S, Yamada S, Lopes TJ, Maemura T, Katsura H, Ozawa M, Watanabe S, Neumann G, Kawaoka Y. Molecular determinants of virulence and stability of a reporter-expressing H5N1 influenza A virus. J Virol 89:11337-11346, 2015.
Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG. Suppressor of cytokine signaling 3 is an inducible host factor during Ebola virus infection that regulates virus egress. J Virol 89:10399-10406, 2015.
Okazaki T, Higuchi M, Takeda K, Iwatsuki-Horimoto K, Kiso M, Miyagishi M, Yanai H, Kato A, Yoneyama M, Fujita T, Taniguchi T, Kawaoka Y, Ichijo H, Gotoh Y. The ASK family kinases differentially mediate induction of type I interferon and apoptosis during the antiviral response. Sci Signal 8:ra78, 2015.
Hill-Batorski L, Halfmann P, Marzi A, Lopes TJ, Neumann G, Feldmann H, Kawaoka Y. Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection. J Infect Dis 212:S329-S335, 2015.
Ping J, Lopes T.J.S, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y. Development of high-yield influenza A virus vaccine viruses. Nat Commun 6:8148, 2015.
Oishi K, Yamayoshi S, Kawaoka Y. Mapping of a region of the PA-X protein of influenza A virus that is important for its shut-off activity. J Virol 89:8661-8665, 2015.
Uraki R, Piao Z, Akeda Y, Iwatsuki-Horimoto K, Kiso M, Ozawa M, Oishi K, Kawaoka Y. A bivalent vaccine based on a PB2-knockout influenza virus protects mice from secondary pneumococcal pneumonia. J Infect Dis 212: 1939-1948, 2015.
Taft AS, Ozawa M, Fitch A, Depasse JV, Halfmann PJ, Hill-Batorski L, Hatta M, Friedrich TC, Lopes TJS, Maher EA, Ghedin E, Macken CA, Neumann B, Kawaoka Y. Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. Nat Commun 6:7491, 2015.
Shoemaker JE, Fukuyama S, Eisfeld AJ, Zhao D, Kawakami E, Sakabe S, Maemura T, Gorai T, Katsura H, Muramoto Y, Watanabe S, Watanabe T, Fuji K, Matsuoka Y, Kitano H, Kawaoka Y. An ultrasensitive mechanism regulates influenza virus-induced inflammation. PLoS Pathog e1004856, 2015.
Chin AW, Perera RA, Guan Y, Halfmann P, Kawaoka Y, Peiris M, Poon LL. Pseudoparticle Neutralization Assay for Detecting Ebola Neutralizing Antibodies in Biosafety Level 2 Settings. Clin Chem 61:885-886, 2015.
Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 348:439-442, 2015.
Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. Nat Commun. 6:6600, 2015.
Takashita E, Kiso M, Fujisaki S, Yokoyama M, Nakamura K, Shirakura M, Sato H, Odagiri T, Kawaoka Y, Tashiro M; The Influenza Virus Surveillance Group of Japan. Characterization of a large cluster of influenza A(H1N1)pdm09 virus cross-resistant to oseltamivir and peramivir during the 2013/2014 influenza season in Japan. Antimicrob Agents Chemother59:2607-2617, 2015.
Yamaji R, Yamada S, Le MQ, Ito M, Sakai-Tagawa Y, Kawaoka Y. Mammalian adaptive mutations of the PA protein of highly pathogenic avian H5N1 influenza virus. J Virol 89:4117-4125, 2015.
Yamayoshi S, Fukuyama S, Yamada S, Zhao D, Murakami S, Uraki R, Watanabe T, Tomita Y, Neumann G, Kawaoka Y. Amino acids substitutions in the PB2 protein of H7N9 influenza A viruses are important for virulence in mammalian hosts. Sci Rep5:8039, 2015.
Yamaji R, Yamada S, Le MQ, Li C, Chen H, Qurnianingsih E, Nidom CA, Ito M, Sakai-Tagawa Y, Kawaoka Y. Identification of PB2 mutations responsible for the efficient replication of H5N1 influenza viruses in human lung epithelial cells. J Virol 89:3947-3956, 2015.

2014

Li X, Shi J, Guo J, Deng G, Zhang Q, Wang J, He X, Wang K, Chen J, Li Y, Fan J, Kong H, Gu C, Guan Y, Suzuki Y, Kawaoka Y, Liu L, Jiang Y, Tian G, Li Y, Bu Z, Chen H. Genetics, receptor binding property, and transmissibility in mammals of naturally isolated H9N2 avian influenza viruses. PLoS Pathog 10:e1004508, 2014.
Peng X, Alföldi J, Gori K, Eisfeld AJ, Tyler SR, Tisoncik-Go J, Brawand D, Law GL, Skunca N, Hatta M, Gasper DJ, Kelly SM, Chang J, Thomas MJ, Johnson J, Berlin AM, Lara M, Russell P, Swofford R, Turner-Maier J, Young S, Hourlier T, Aken B, Searle S, Sun X, Yi Y, Suresh M, Tumpey TM, Siepel A, Wisely SM, Dessimoz C, Kawaoka Y, Birren BW, Lindblad-Toh K, Di Palma F, Engelhardt JF, Palermo RE, Katze MG. The draft genome sequence of the ferret (Mustela putorius furo) facilitates study of human respiratory disease. Nat Biotechnol 32:1250-1255, 2014.
Fan S, Hatta M, Kim JH, Le MQ, Neumann G, Kawaoka Y. Amino Acid Changes in the Influenza A Virus PA Protein That Attenuate Avian H5N1 Viruses in Mammals. J Virol 88:13737-13746, 2014.
Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC. Modified vaccinia virus ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 88:13418-13428, 2014.
Katsura H, Piao Z, Iwatsuki-Horimoto K, Akeda Y, Watanabe S, Horimoto T, Oishi K, Kawaoka Y. A Bivalent Vaccine Based on a Replication-Incompetent Influenza Virus Protects against Streptococcus pneumoniae and Influenza Virus Infection. J Virol88:13410-13417, 2014.
Watanabe T, Kawakami E, Shoemaker JE, Lopes TJS, Matsuoka Y, Tomita Y, Kozuka-Hata H, Gorai T, Kuwahara T, Takeda E, Nagata A, Takano R, Kiso M, Yamashita M, Sakai-Tagawa Y, Katsura H, Nonaka N, Fujii H, Fujii K, Sugita Y, Noda T, Goto H, Fukuyama S, Watanabe S, Neumann G, Oyama M, Kitano H, Kawaoka Y. Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host&Microbe 16:795-805, 2014.
Uraki R, Das SC, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M, Coban C, Ishii KJ, Kawaoka Y. Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine 32:5295-300, 2014.
Nagaoka M, Hatta Y, Kawaoka Y, Malherbe LP. Antigen aignal strength during priming determines effector CD4 T cell function and antigen sensitivity during influenza virus challenge. J Immunol 193:2812-2820, 2014.
Sakai-Tagawa Y, Ozawa M, Yamada S, Uchida Y, Saito T, Takahashi K, Sugaya N, Tashiro M, Kawaoka Y. Detection sensitivity of influenza rapid diagnostic tests. Microbiol Immunol 58:600-606, 2014.
Hatakeyama D, Shoji M, Yamayoshi S, Hirota T, Nagae M, Yanagisawa S, Nakano M, Ohmi N, Noda T, Kawaoka Y, Kuzuhara T. A novel functional site in the PB2 subunit of influenza A virus essential for acetyl-CoA interaction, RNA polymerase activity, and viral replication. J Biol Chem 289:24980-24994, 2014.
Fan S, Hatta M, Kim JH, Halfmann P, Imai M, Macken CA, Le MQ, Nguyen T, Neumann G, Kawaoka Y. Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. Nat Commun 5:5021, 2014.
Garulli B, Di Mario G, Stillitano MG, Compagnoni D, Titti F, Cafaro A, Ensoli B, Kawaoka Y, Castrucci MR.Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice. Biomed Res Int2014:904038, 2014.
Itoh Y, Yoshida R, Shichinohe S, Higuchi M, Ishigaki H, Nakayama M, Pham VL, Ishida H, Kitano M, Arikata M, Kitagawa N, Mitsuishi Y, Ogasawara K, Tsuchiya H, Hiono T, Okamatsu M, Sakoda Y, Kida H, Ito M, Quynh Mai L, Kawaoka Y, Miyamoto H, Ishijima M, Igarashi M, Suzuki Y, Takada A. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection. PLoS Pathog. 10:e1004192, 2014.
Josset L, Tchitchek N, Gralinski LE, Ferris MT, Eisfeld AJ, Green RR, Thomas MJ, Tisoncik-Go J, Schroth GP, Kawaoka Y, Manuel de Villena FP, Baric RS, Heise MT, Peng X, Katze MG. Annotation of long non-coding RNAs expressed in Collaborative Cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts. RNA Biol 11(7), 2014.
Kitano M, Itoh Y, Ishigaki H, Nakayama M, Ishida H, Pham VL, Arikata M, Shichinohe S, Tsuchiya H, Kitagawa N, Kobayashi M, Yoshida R, Sato A, Le QM, Kawaoka Y, Ogasawara K. Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques. Antimicrob Agents Chemother 58:4795-4803, 2014.
Muramoto Y, Shoemaker JE, Le MQ, Itoh Y, Tamura D, Sakai-Tagawa Y, Imai H, Uraki R, Takano R, Kawakami E, Ito M, Okamoto K, Ishigaki H, Mimuro H, Sasakawa C, Matsuoka Y, Noda T, Fukuyama S, Ogasawara K, Kitano H, Kawaoka Y. Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses. J Virol 88:8981-8997, 2014.
Menachery VD, Eisfeld AJ, Schäfer A, Josset L, Sims AC, Proll S, Fan S, Li C, Neumann G, Tilton SC, Chang J, Gralinski LE, Long C, Green R, Williams CM, Weiss J, Matzke MM, Webb-Robertson BJ, Schepmoes AA, Shukla AK, Metz TO, Smith RD, Waters KM, Katze MG, Kawaoka Y, Baric RS. Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses. mBio 5:e01174-14, 2014.
Sugaya N, Sakai-Tagawa Y, Bamba M, Yasuhara R, Yamazaki M, Kawakami C, Yamaguchi Y, Ide Y, Ichikawa M, Mitamura K, Kawaoka Y. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antivir Ther 20:49-55, 2015.
Watanabe T, Zhong G, Russell CA, Nakajima N, Hatta M, Hanson A, McBride R, Burke DF, Takahashi K, Fukuyama S, Tomita Y, Maher A, Watanabe S, Imai M, Neumann G, Hasegawa H, Paulson JC, Smith DJ, Kawaoka Y. Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential. Cell Host&Microbe 15:692-705, 2014.
Kurebayashi Y, Takahashi T, Otsubo T, Ikeda K, Takahashi S, Takano M, Agarikuchi T, Sato T, Matsuda Y, Minami A, Kanazawa H, Uchida Y, Saito T, Kawaoka Y, Yamada T, Kawamori F, Thomson R, von Itzstein M, Suzuki T. Imaging of influenza virus sialidase activity in living cells. Sci Rep 4:4877, 2014.
Tani H, Iha K, Shimojima M, Fukushi S, Taniguchi S, Yoshikawa T, Kawaoka Y, Nakasone N, Ninomiya H, Saijo M, Morikawa S. Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus. J Virol 88:7317-7330, 2014.
Garulli B, Di Mario G, Stillitano MG, Kawaoka Y, Castrucci MR. Exploring mucosal immunization with a recombinant influenza virus carrying an HIV-polyepitope in mice with pre-existing immunity to influenza. Vaccine 32:2501-2506, 2014.
Teijaro JR, Walsh KB, Long JP, Tordoff KP, Stark GV, Eisfeld AJ, Kawaoka Y, Rosen H, Oldstone MB. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology 452-453:152-157, 2014.
Sakai K, Ami Y, Tahara M, Kubota T, Anraku M, Abe M, Nakajima N, Sekizuka T, Shirato K, Suzaki Y, Ainai A, Nakatsu Y, Kanou K, Nakamura K, Suzuki T, Komase K, Nobusawa E, Maenaka K, Kuroda M, Hasegawa H, Kawaoka Y, Tashiro M, Takeda M. The Host Protease TMPRSS2 Plays a Major Role in In Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses. J Virol88:5608-5616, 2014.
Neumann G, Macken CA, Kawaoka Y. Identification of amino acid changes that may have been critical for the genesis of A(H7N9) influenza viruses. J Virol 88: 4877-4896, 2014.
Liu Z, Kato A, Shindo K, Noda T, Sagara H, Kawaoka Y, Arii J, Kawaguchi Y. Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34 and Us3, and regulates viral nuclear egress. J Virol 88: 4657-4667, 2014.
Wang G, Deng G, Shi J, Luo W, Zhang G, Zhang Q, Liu L, Jiang Y, Li C, Sriwilaijaroen N, Hiramatsu H, Suzuki Y, Kawaoka Y, Chen H. H6 influenza viruses pose a potential threat to human health. J Virol 88: 3953-3964, 2014.
Castrucci MR, Facchini M, Di Mario G, Garulli B, Sciaraffia E, Meola M, Fabiani C, De Marco MA, Cordioli P, Siccardi A, Kawaoka Y, Donatelli I. Modified vaccinia virus Ankara expressing the hemagglutinin of pandemic (H1N1) 2009 virus induces cross-protective immunity against Eurasian 'avian-like' H1N1 swine viruses in mice. Influenza Other Respir Viruses 8: 367-375, 2014.
Yamayoshi S, Yamada S, Fukuyama S, Murakami S, Zhao D, Uraki R, Watanabe T, Tomita Y, Macken C, Neumann G, Kawaoka Y. Virulence-affecting amino acid changes in the PA protein of H7N9 influenza A viruses. J Virol 88: 3127-3134, 2014.
Horimoto T, Gen F, Murakami S, Iwatsuki-Horimoto K, Kato K, Akashi H, Hisasue M, Sakaguchi M, Kawaoka Y, Maeda K. Serological evidence of infection of dogs with human influenza viruses in Japan. Vet Rec 174: 96, 2014.
Fonseca W, Ozawa M, Hatta M, Orozco E, Martínez MB, Kawaoka Y. A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus. Arch Virol 159: 1067-1077, 2014.
de Vries RP, Zhu X, McBride R, Rigter A, Hanson A, Zhong G, Hatta M, Xu R, Yu W, Kawaoka Y, de Haan CA, Wilson IA, Paulson JC. Hemagglutinin receptor specificity and structural analyses of respiratory droplet transmissible H5N1 viruses. J Virol 88:768-773, 2014.

2013

Nakayama M, Shichinohe S, Itoh Y, Ishigaki H, Kitano M, Arikata M, Pham VL, Ishida H, Kitagawa N, Okamatsu M, Sakoda Y, Ichikawa T, Tsuchiya H, Nakamura S, Le QM, Ito M, Kawaoka Y, Kida H, Ogasawara K. Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine. PLoS One 8:e82740, 2013.
Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, O'Connor DH, Hughes AL, Neumann G, Kawaoka Y, Friedrich TC. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat Commun 4:2636, 2013.
Kobayashi H, Iwatsuki-Horimoto K, Kiso M, Uraki R, Ichiko Y, Takimoto T, Kawaoka Y. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine. Vaccine 31:6239-6246, 2013.
Hill-Batorski L, Halfmann P, Neumann G, Kawaoka Y. The Cytoprotective Enzyme Heme Oxygenase-1 Suppresses Ebola virus Replication. J Virol 87: 13795-13802, 2013.
Matsuoka Y, Matsumae H, Katoh M, Eisfeld AJ, Neumann G, Hase T, Ghosh S, Shoemaker JE, Lopes TJ, Watanabe T, Watanabe S, Fukuyama S, Kitano H, Kawaoka Y. A comprehensive map of the influenza A virus replication cycle. BMC Syst Biol 7:97, 2013.
Sugita Y, Sagara H, Noda T, Kawaoka Y. Configuration of viral ribonucleoprotein complexes within the influenza A virion. J Virol 87: 12879-12884, 2013.
Bornholdt ZA, Noda T, Abelson DM, Halfmann P, Wood MR, Kawaoka Y, Saphire EO. Structural rearrangement of Ebola virus VP40 begets multiple functions in the virus life cycle. Cell 154:763-774, 2013.
Mitchell HD, Eisfeld AJ, Sims AC, McDermott JE, Matzke MM, Webb-Robertson BJ, Tilton SC, Tchitchek N, Josset L, Li C, Ellis AL, Chang JH, Heegel RA, Luna ML, Schepmoes AA, Shukla AK, Metz TO, Neumann G, Benecke AG, Smith RD, Baric RS, Kawaoka Y, Katze MG, Waters KM. A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses. PLoS One 8:e69374, 2013.
Goto H, Muramoto Y, Noda T, Kawaoka Y. The genome packaging signal of the influenza A virus genome comprises a genome incorporation signal and a genome bundling signal. J Virol87: 11316-11322, 2013.
Tchitchek N, Eisfeld AJ, Tisoncik-Go J, Josset L, Gralinski LE, Bécavin C, Tilton SC, Webb-Robertson BJ, Ferris MT, Totura AL, Li C, Neumann G, Metz TO, Smith RD, Waters KM, Baric R, Kawaoka Y, Katze MG. Specific mutations in H5N1 mainly impact the magnitude and velocity of the host response in mice. BMC Syst Biol 7:69, 2013.
Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. Characterization of H7N9 influenza A viruses isolated from humans.Nature 501:551-555, 2013.
Deng G, Tan D, Shi J, Cui P, Jiang Y, Liu L, Tian G, Kawaoka Y, Li C, Chen H. Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the Dongting Lake region of China. J Virol 87:9452-9462, 2013.
Gibbs DL, Baratt A, Baric RS, Kawaoka Y, Smith RD, Orwoll ES, Katze MG, McWeeney SK. Protein co-expression network analysis (ProCoNA). J Clin Bioinforma 3:11, 2013.
Takahashi T, Song J, Suzuki T, Kawaoka Y. Mutations in NA that induced low pH-stability and enhanced the replication of pandemic (H1N1) 2009 influenza A virus at an early stage of the pandemic. PLoS One 8:e64439, 2013.
Takahashi K, Halfmann P, Oyama M, Kozuka-Hata H, Noda T, Kawaoka Y. DNA Topoisomerase 1 Facilitates the Transcription and Replication of the Ebola Virus Genome. J Virol 87:8862-8869, 2013.
Uraki R, Kiso M, Iwatsuki-Horimoto K, Fukuyama S, Takashita E, Ozawa M, Kawaoka Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J Virol87:7874-7881, 2013.
Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, Locher K, Walker PA, Collins PJ, Kawaoka Y, Skehel JJ, Gamblin SJ. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 497:392-396, 2013.
Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 18(15), 2013.
Kiso M, Takano R, Sakabe S, Katsura H, Shinya K, Uraki R, Watanabe S, Saito H, Toba M, Kohda N, Kawaoka Y. Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Sci Rep 3:1563, 2013.
Morita M, Kuba K, Ichikawa A, Nakayama M, Katahira J, Iwamoto R, Watanebe T, Sakabe S, Daidoji T, Nakamura S, Kadowaki A, Ohto T, Nakanishi H, Taguchi R, Nakaya T, Murakami M, Yoneda Y, Arai H, Kawaoka Y, Penninger JM, Arita M, Imai Y. The lipid mediator protectin d1 inhibits influenza virus replication and improves severe influenza. Cell 153:112-125, 2013.
Watanabe T, Tisoncik-Go J, Tchitchek N, Watanabe S, Benecke AG, Katze MG, Kawaoka Y. 1918 HA and the viral RNA polymerase complex enhance viral pathogenicity, but only HA induces aberrant host responses in mice. J Virol 87:5239-5254, 2013.
Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi, Nidom CA, Chen H, Neumann G, Kawaoka Y. Synergistic effect of the PDZ and the p85β-binding domains of the NS1 protein in virulence of an avian H5N1 influenza A virus. J Virol 87:4861-4871, 2013.
Nanbo A, Watanabe S, Halfmann P, Kawaoka Y. The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. Sci Rep 3:1206, 2013.
Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep 3:1106, 2013.
Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW; H1N1pdm serology working group. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respi Viruses 7:872-876, 2013.
Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 110:1893-1898, 2013.
Schaefer MH, Lopes TJ, Mah N, Shoemaker JE, Matsuoka Y, Fontaine JF, Louis-Jeune C, Eisfeld AJ, Neumann G, Perez-Iratxeta C, Kawaoka Y, Kitano H, Andrade-Navarro MA. Adding protein context to the human protein-protein interaction network to reveal meaningful interactions. PLoS Comput Biol e1002860, 2013.
Fehling SK, Noda T, Maisner A, Lamp B, Conzelmann KK, Kawaoka Y, Klenk HD, Garten W, Strecker T. The microtubule motor protein KIF13A is involved in intracellular trafficking of the Lassa virus matrix protein Z. Cell Microbiol 15:315-334, 2013.
Gen F, Yamada S, Kato K, Akashi H, Kawaoka Y, Horimoto T. Attenuation of an influenza A virus due to alteration of its hemagglutinin-neuraminidase functional balance in mice. Arch Virol 158:1003-1011, 2013
Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y. Identification of novel influenza A virus proteins translated from PA mRNA. J Virol 87:2455-2462, 2013.
Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y. Virulence determinants of pandemic A(H1N1)2009 virus in a mouse model. J Virol 87:2226-2233, 2013.
Ichikawa A, Kuba K, Morita M, Chida S, Tezuka H, Hara H, Sasaki T, Ohteki T, Ranieri VM, Dos Santos CC, Kawaoka Y, Akira S, Luster AD, Lu B, Penninger JM, Uhlig S, Slutsky AS, Imai Y. CXCL10-CXCR3 Enhances the Development of Neutrophil-mediated Fulminant Lung Injury of Viral and Non-viral Origin. Am J Respir Crit Care Med 187:65-77, 2013.
Takano R, Kiso M, Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the NA of H5N1 avian influenza viruses. J Infect Dis 207:89-97, 2013.
Ebihara H, Zivcec M, Gardner D, Falzarano D, Lacasse R, Rosenke R, Long D, Haddock E, Fischer E, Kawaoka Y, Feldmann H. A Syrian Golden Hamster Model Recapitulating Ebola Hemorrhagic Fever. J Infect Dis 207:306-318, 2013.
Sakabe S, Takano R, Nagamura-Inoue T, Yamashita N, Nidom CA, Quynh Le MT, Iwatsuki-Horimoto K, Kawaoka Y. Differences in Cytokine Production in Human Macrophages and in Virulence in Mice Are Attributable to the Acidic Polymerase Protein of Highly Pathogenic Influenza A Virus Subtype H5N1. J Infect Dis 207:262-271, 2013.

2012

Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y.Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. FEBS Open Bio 2:261-265, 2012.
Haraguchi H, Noda T, Kawaoka Y, Morikawa Y. A Large Extension to HIV-1 Gag, Like Pol, Has Negative Impacts on Virion Assembly. PLoS One 7:e478282012, 2012.
Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, Matsuno K, Feldmann H, Yoshida R, Kawaoka Y, Takada A. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol 86:13467-13474, 2012.
Bale S, Julien JP, Bornholdt ZA, Kimberlin CR, Halfmann P, Zandonatti MA, Kunert J, Kroon GJ, Kawaoka Y, Macrae IJ, Wilson IA, Saphire EO. Marburg Virus VP35 Can Both Fully Coat the Backbone and Cap the Ends of dsRNA for Interferon Antagonism. PLoS Pathog 8:e1002916, 2012.
Takashita E, Muraki Y, Sugawara K, Asao H, Nishimura H, Suzuki K, Tsuji T, Hongo S, Ohara Y, Kawaoka Y, Ozawa M, Matsuzaki Y. Intrinsic Temperature Sensitivity of Influenza C Virus Hemagglutinin-Esterase-Fusion Protein. J Virol 86:13108-13111, 2012.
Das SC, Hatta M, Wilker PR, Myc A, Hamouda T, Neumann G, Baker JR Jr, Kawaoka Y. Nanoemulsion W(80)5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 30:6871-6877, 2012.
Shoemaker JE, Lopes TJ, Ghosh S, Matsuoka Y, Kawaoka Y, Kitano H. CTen: a web-based platform for identifying enriched cell types from heterogeneous microarray data. BMC Genomics 13:460, 2012.
Shoemaker JE, Fukuyama S, Eisfeld AJ, Muramoto Y, Watanabe S, Watanabe T, Matsuoka Y, Kitano H, Kawaoka Y. Integrated network analysis reveals a novel role for the cell cycle in 2009 pandemic influenza virus-induced inflammation in macaque lungs. BMC Syst Biol. 6:117, 2012.
Kingstad-Bakke B, Brewoo JN, Mai LQ, Kawaoka Y, Osorio JE. Effects of route and co-administration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice. Vaccine 30:6402-6408, 2012.
Ilyushina NA, Ikizler MR, Kawaoka Y, Rudenko LG, Treanor JJ, Subbarao K, Wright PF. Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol 86:11725-11734, 2012.
Imai M, Watanabe S, Kawaoka Y. The Cytoplasmic Tail Domain of Influenza B Virus Hemagglutinin Is Important for Its Incorporation into Virions but Is Not Essential for Virus Replication in Cell Culture in the Presence of Compensatory Mutations. J Virol 86:11633-11644, 2012.
Katsura H, Iwatsuki-Horimoto K, Fukuyama S, Watanabe S, Sakabe S, Hatta Y, Murakami S, Shimojima M, Horimoto T, Kawaoka Y. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. Vaccine30:6027-6033, 2012.
Inagaki A, Goto H, Kakugawa S, Ozawa M, Kawaoka Y. Competitive incorporation of homologous gene segments of influenza A virus into virions. J Virol 86:10200-10202, 2012.
Zhang Y, Zhang Q, Gao Y, He X, Kong H, Jiang Y, Guan Y, Xia X, Shu Y, Kawaoka Y, Bu Z, Chen H. Key molecular factors in HA and PB2 contribute to the efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol 86:9666-9674, 2012.
Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, James SL, Herfst S, van Boheemen S, Linster M, Schrauwen EJ, Katzelnick L, Mosterín A, Kuiken T, Maher E, Neumann G, Osterhaus AD, Kawaoka Y, Fouchier RA, Smith DJ. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336:1541-1547, 2012.
Watanabe T, Imai M, Watanabe S, Shinya K, Hatta M, Li C, Neumann G, Ozawa M, Hanson A, Zhong G, Fukuyama S, Kawakami E, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Kilander A, Dudman SG, Suresh M, Hungnes O, Friedrich TC, Kawaoka Y. Characterization in vitro and in vivo of pandemic (H1N1) 2009 viruses isolated from patients. J Virol 86:9361-9368, 2012.
Kouris NA, Schaefer JA, Hatta M, Freeman BT, Kamp TJ, Kawaoka Y, Ogle BM. Directed fusion of mesenchymal stem cells with cardiomyocytes via VSV-G facilitates stem cell programming. Stem Cells Int 2012:414038, 2012.
Shimojima M, Kawaoka Y. Cell Surface molecules involved in infection mediated by lymphocytic choriomeningitis virus gycoprotein. J Vet Med Sci 74:1363-1366, 2012.
Chu C, Fan S, Li C, Macken C, Kim JH, Hatta M, Neumann G, Kawaoka Y. Functional analysis of conserved motifs in influenza virus PB1 protein. PLoS One 7:e36113, 2012.
Kikuchi T, Iwatsuki-Horimoto K, Adachi E, Koga M, Nakamura H, Hosoya N, Kawana-Tachikawa A, Koibuchi T, Miura T, Fujii T, Kawaoka Y, Iwamoto A. Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults. Vaccine 30:3819-3823, 2012.
Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 86:6055-6066, 2012.
Bharat TA, Noda T, Riches JD, Kraehling V, Kolesnikova L, Becker S, Kawaoka Y, Briggs JA. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci U S A 109:4275-4280, 2012.
Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. Experimental adaptation of an influenza H5 haemagglutinin confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428, 2012.
Gorai T, Goto H, Noda T, Watanabe T, Kozuka-Hata H, Oyama M, Takano R, Neumann G, Watanabe S, Kawaoka Y. The F1Fo-ATPase at the plasma membrane is critical for efficient influenza virus budding. Proc Natl Acad Sci USA 109:4615-4620, 2012.
Nidom CA, Yamada S, Nidom RV, Rahmawati K, Alamudi MY, Kholik, Indrasari S, Hayati RS, Iwatsuki-Horimoto K, Kawaoka Y. Genetic characterization of H5N1 influenza viruses isolated from chickens in Indonesia in 2010. Virus Genes 44:459-465, 2012.
Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J Virol 86:4123-4128, 2012.
Kawai Y, Kimura Y, Lezhava A, Kanamori H, Usui K, Hanami T, Soma T, Morlighem JÉ, Saga S, Ishizu Y, Aoki S, Endo R, Oguchi-Katayama A, Kogo Y, Mitani Y, Ishidao T, Kawakami C, Kurata H, Furuya Y, Saito T, Okazaki N, Chikahira M, Hayashi E, Tsuruoka S, Toguchi T, Saito Y, Ban T, Izumi S, Uryu H, Kudo K, Sakai-Tagawa Y, Kawaoka Y, Hirai A, Hayashizaki Y, Ishikawa T. One-step detection of the 2009 pandemic influenza A(H1N1) virus by the RT-SmartAmp assay and its clinical validation.PLoS One 7:e30236, 2012.
Shi J, Wen Z, Guo J, Zhang Y, Deng G, Shu Y, Wang D, Jiang Y, Kawaoka Y, Bu Z, Chen H. Protective efficacy of an H1N1 cold-adapted live vaccine against the 2009 pandemic H1N1, seasonal H1N1, and H5N1 influenza viruses in mice. Antiviral Res93:346-353, 2012.
Noda T, Sugita Y, Aoyama K, Hirase A, Kawakami E, Miyazawa A, Sagara H, Kawaoka Y. Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat Commun 3:639, 2012.
Olal D, Kuehne A, Bale S, Halfmann P, Hashiguchi T, Fusco ML, Lee JE, King LB, Kawaoka Y, Dye JM Jr, Saphire EO. Structure of an Ebola virus-protective antibody in complex with its mucin-domain linear epitope. J Virol 86:2809-2816, 2012.
Shimojima M, Ströher U, Ebihara H, Feldmann H, Kawaoka Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol 86:2067-2078, 2012.
Das SC, Watanabe S, Hatta M, Noda T, Neumann G, Ozawa M, Kawaoka Y. The arginine residues at positions 76-78 of influenza A virus matrix protein M1 play an important role in viral replication. J Virol ;86:1522-1530, 2012.
Murakami S, Horimoto T, Ito M, Takano R, Katsura H, Shimojima M, Kawaoka Y. Enhanced growth of influenza vaccine seed viruses in Vero cells mediated by broadening the optimal pH range for virus membrane fusion. J Virol 86:1405-1410, 2012.
Yamada S, Shinya K, Takada A, Ito T, Suzuki T, Suzuki Y, Le QM, Ebina M, Kasai N, Kida H, Horimoto T, Rivailler P, Chen LM, Donis RO, Kawaoka Y. Adaptation of a duck influenza A virus in quail. J Virol 86:1411-1420, 2012.
Shinya K, Ito M, Makino A, Tanaka M, Miyake K, Eisfeld AJ, Kawaoka Y. The TLR4-TRIF pathway protects against H5N1 influenza virus infection. J Virol 86:19-24, 2012.
Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, Kawaoka Y. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J Virol 86:121-127, 2012.

2011

Peng X, Gralinski L, Ferris MT, Frieman MB, Thomas MJ, Proll S, Korth MJ, Tisoncik JR, Heise M, Luo S, Schroth GP, Tumpey TM, Li C, Kawaoka Y, Baric RS, Katze MG. Integrative deep sequencing of the mouse lung transcriptome reveals differential expression of diverse classes of small RNAs in response to respiratory virus infection. mBio e00198-11, 2011.
Weinfurter JT, Brunner K, Capuano SV 3rd, Li C, Broman KW, Kawaoka Y, Friedrich TC. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 7:e1002381, 2011.
Dias JM, Kuehne AI, Abelson DM, Bale S, Wong AC, Halfmann P, Muhammad MA, Fusco ML, Zak SE, Kang E, Kawaoka Y, Chandran K, Dye JM, Saphire EO. A shared structural solution for neutralizing Ebolaviruses. Nat Struct Mol Biol 18:1424-1427, 2011.
McDermott JE, Shankaran H, Eisfeld AJ, Belisle SE, Neumann G, Li C, McWeeney SK, Sabourin CL, Kawaoka Y, Katze MG, Waters KM. Conserved host response to highly pathogenic avian influenza virus infection in human cell culture, mouse and macaque model systems. BMC Syst Biol 5:190, 2011.
Garulli B, Di Mario G, Sciaraffia E, Kawaoka Y, Castrucci MR. Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin. J Biomed Biotechnol 497364, 2011.
Halfmann P, Neumann G, Kawaoka Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J Infect Dis 204 Suppl 3:S953-956, 2011.
Iwasa A, Halfmann P, Noda T, Oyama M, Kozuka-Hata H, Watanabe S, Shimojima M, Watanabe T, Kawaoka Y. Contribution of Sec61α to the life cycle of Ebola virus. J Infect Dis 204 Suppl 3:S919-926, 2011.
Iwasa A, Shimojima M, Kawaoka Y. sGP serves as a structural protein in Ebola virus infection. J Infect Dis 204 Suppl 3:S897-903, 2011.
Noda T, Kolesnikova L, Becker S, Kawaoka Y. The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation. J Infect Dis 204 Suppl 3:S878-883, 2011.
Makino A, Yamayoshi S, Shinya K, Noda T, Kawaoka Y. Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding. J Infect Dis 204 Suppl 3:S871-877, 2011.
Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y. Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults. Vaccine 29:9224-9228, 2011
Watanabe T, Shinya K, Watanabe S, Imai M, Hatta M, Li C, Wolter BF, Neumann G, Hanson A, Ozawa M, Yamada S, Imai H, Sakabe S, Takano R, Iwatsuki-Horimoto K, Kiso M, Ito M, Fukuyama S, Kawakami E, Gorai T, Simmons HA, Schenkman D, Brunner K, Capuano SV 3rd, Weinfurter JT, Nishio W, Maniwa Y, Igarashi T, Makino A, Travanty EA, Wang J, Kilander A, Dudman SG, Suresh M, Mason RJ, Hungnes O, Friedrich TC, Kawaoka Y. Avian-type receptor-binding ability can increase influenza virus pathogenicity in macaques. J Virol. 85:13195-13203, 2011.
Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y. Replication-incompetent influenza A viruses that stably express a foreign gene. J Gen Virol 92:2879-2888, 2011.
Li C, Bankhead A 3rd, Eisfeld AJ, Hatta Y, Jeng S, Chang JH, Aicher LD, Proll S, Ellis AL, Law GL, Waters KM, Neumann G, Katze MG, McWeeney S, Kawaoka Y. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus. J Virol 85:10955-10967, 2011.
Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H. A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 85:10989-10998, 2011.
Lopes TJ, Schaefer M, Shoemaker J, Matsuoka Y, Fontaine JF, Neumann G, Andrade-Navarro MA, Kawaoka Y, Kitano H. Tissue specific subnetworks and characteristics of publicly available human protein interaction databases. Bioinformatics 27:2414-2421, 2011.
Sugita Y, Noda T, Sagara H, Kawaoka Y. Ultracentrifugation deforms unfixed influenza A virions. J Gen Virol 92:2485-2493, 2011.
Eisfeld AJ, Neumann G, Kawaoka Y. HRB is essential for iInfluenza A virus replication and promotes genome trafficking in late-stage infection. J Virol 85:9588-9598, 2011.
Cilloniz C, Ebihara H, Ni C, Neumann G, Korth MJ, Kelly SM, Kawaoka Y, Feldmann H, Katze MG. Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol85:9060-9068, 2011.
Yan P, Zhao Y, Zhang X, Xu D, Dai X, Teng Q, Yan L, Zhou J, Ji X, Zhang S, Liu G, Zhou Y, Kawaoka Y, Tong G, Li Z. An infectious disease of ducks caused by a newly emerged Tembusu virus strain in mainland China. Virology 417:1-8, 2011.
Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, Kawaoka Y, Rosen H, Oldstone MB. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A 108:12018-12023, 2011.
Yamaoka M, Palilingan JF, Wibisono J, Yudhawati R, Nidom RV, Alamudi MY, Ginting TE, Makino A, Nidom CA, Shinya K, Kawaoka Y. Virological surveillance of human influenza in Indonesia, October 2008-March 2010. Microbiol Immunol 55:514-517, 2011.
Poetranto ED, Yamaoka M, Nastri AM, Krisna LA, Rahman MH, Wulandari L, Yudhawati R, Ginting TE, Makino A, Shinya K, Kawaoka Y. An H5N1 highly pathogenic avian influenza virus isolated from a local tree sparrow in Indonesia. Microbiol Immunol 55:666-672, 2011.
Octaviani CP, Goto H, Kawaoka Y. Reassortment between seasonal H1N1 and pandemic (H1N1) 2009 influenza viruses is restricted by limited compatibility among polymerase subunits. J Virol 85:8449-8452, 2011.
Morlighem JÉ, Aoki S, Kishima M, Hanami M, Ogawa C, Jalloh A, Takahashi Y, Kawai Y, Saga S, Hayashi E, Ban T, Izumi S, Wada A, Mano M, Fukunaga M, Kijima Y, Shiomi M, Inoue K, Hata T, Koretsune Y, Kudo K, Himeno Y, Hirai A, Takahashi K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kawaoka Y, Hayashizaki Y, Ishikawa T. Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. PLoS One 6:e18956, 2011.
Eisfeld AJ, Kawakami E, Watanabe T, Neumann G, Kawaoka Y. RAB11A is essential for influenza genome transport to the plasma membrane. J Virol 85:6117-6126, 2011.
Shimizu K, Li C, Muramoto Y, Yamada S, Arikawa J, Chen H, Kawaoka Y. The NP and M segments of H5N1 influenza viruses are responsible for dominance in embryonated eggs. J Gen Virol 92:1645-1649, 2011.
Horimoto T, Maeda K, Murakami S, Kiso M, Iwatsuki-Horimoto K, Sashika M, Ito T, Suzuki K, Yokoyama M, Kawaoka Y. Highly pathogenic avian influenza virus infection in feral raccoons, Japan. Emerg Infect Dis 4:714-717, 2011.
Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res 158:124-129, 2011.
Tomita Y, Noda T, Fujii K, Watanabe T, Morikawa Y, Kawaoka Y. The cellular factors Vps18 and Mon2 are required for efficient production of infectious HIV-1 particles. J Virol 85:5618-5627, 2011.
Shinya K, Makino A, Tanaka H, Hatta M, Watanabe T, Le MQ, Imai H, Kawaoka Y. Systemic dissemination of H5N1 influenza A viruses in ferrets and hamsters after direct intragastric inoculation. J Virol 85:4673-4678, 2011.
Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. Subclinical brain injury caused by H5N1 influenza virus infection. J Virol 85:5202-5207, 2011.
Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, Noda T, Horimoto T, Kawaoka Y. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 85:4667-4672, 2011.
Ozawa M, Basnet S, Burley LM, Neumann G, Hatta M, Kawaoka Y. Impact of amino acid mutations in PB2, PB1-F2, and NS1 on the replication and pathogenicity of pandemic (H1N1) 2009 influenza viruses. J Virol 85:4596-4601, 2011.
Shtanko O, Watanabe S, Jasenosky LD, Watanabe T, Kawaoka Y. ALIX/AIP1 is required for NP incorporation into Mopeia Z-induced VLPs. J Virol 85:3631-3641, 2011.
Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le MT, Nagamura-Inoue T, Horimoto T, Yamashita N, Kawaoka Y. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol 92:1428-1434, 2011.
Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y. Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 8:97, 2011.
Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S, Ebihara Y, Koibuchi T, Fujii T, Takahashi K, Shimojima M, Sakai-Tagawa Y, Ito M, Sakabe S, Iwasa A, Takahashi K, Ishii T, Gorai T, Tsuji K, Iwamoto A, Kawaoka Y. Sero-prevalence of pandemic (H1N1) 2009 influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol 18:860-866, 2011.
Tamura D, Sugaya N, Ozawa M, Takano R, Ichikawa M, Yamazaki M, Kawakami C, Shimizu H, Uehara R, Kiso M, Kawakami E, Mitamura K, Kawaoka Y. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 52:432-437, 2011.
Hatta Y, Hatta M, Bilsel P, Neumann G, Kawaoka Y. An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus. Vaccine 29:2308-2312, 2011.
Octaviani CP, Li C, Noda T, Kawaoka Y. Reassortment between seasonal and swine-origin H1N1 influenza viruses generates viruses with enhanced growth ability in cell culture. Virus Res 156:147-150, 2011.
Akarsu H, Iwatsuki-Horimoto K, Noda T, Kawakami E, Katsura H, Baudin F, Horimoto T, Kawaoka Y. Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Res 155:240-248, 2011.
Shiozaki T, Iwai A, Kawaoka Y, Takada A, Kida H, Miyazaki T. Requirement of Siva-1 for replication of influenza A virus through apoptosis induction. J Gen Virol 92:315-325, 2011.
Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Alpuche Aranda C, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H. Pandemic swine-origin H1N1 influenza A isolates show heterogeneous virulence in macaques. J Virol 85:1214-1223, 2011.
Song J, Feng H, Xu J, Zhao D, Shi J, Li Y, Deng G, Jiang Y, Li X, Zhu P, Guan Y, Bu Z, Kawaoka Y, Chen H. The PA protein directly contributes to the virulence of H5N1 avian influenza viruses in domestic ducks. J Virol 85:2180-2188, 2011.
Kawakami E, Watanabe T, Fujii K, Goto H, Watanabe S, Noda T, Kawaoka Y. Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA. J Virol Methods 173:1-6, 2011.
Hatakeyama S, Ozawa M, Kawaoka Y. In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Clin Microbiol Infect 17:1332-1335, 2011.

2010

Takahashi T, Kurebayashi Y, Ikeya K, Mizuno T, Fukushima K, Kawamoto H, Kawaoka Y, Suzuki Y, Suzuki T. The low-pH stability discovered in neuraminidase of 1918 pandemic influenza A virus enhances virus replication. PLoS One 5:e15556, 2010.
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, Lipkin WI, Negredo AI, Netesov SV, Nichol ST, Palacios G, Peters CJ, Tenorio A, Volchkov VE, Jahrling PB. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155:2083-2103, 2010.
Haraguchi H, Sudo S, Noda T, Momose F, Kawaoka Y, Morikawa Y. Intracellular localization of human immunodeficiency virus type 1 Gag and GagPol products and virus particle release: relationship with the Gag-to-GagPol ratio. Microbiol Immunol54:734-746, 2010.
Arii J, Goto H, Suenaga T, Oyama M, Kozuka-Hata H, Imai T, Minowa A, Akashi H, Arase H, Kawaoka Y, Kawaguchi Y. Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 467:859-862, 2010.
Sakabe S, Iwastuki-Horimotoa K, Horimoto T, Nidom CA, Le QM, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.Antiviral Res 88:249-255, 2010.
Yamayoshi S, Neumann G, Kawaoka Y. Role of the GTPase Rab1b in ebolavirus particle formation. J Virol. 84:4816-4820, 2010.
Monteerarat Y, Sakabe S, Ngamurulert S, Srichatraphimuk S, Jiamtom W, Chaichuen K, Thitithanyanont A, Permpikul P, Songserm T, Puthavathana P, Nidom CA, Mai le Q, Iwatsuki-Horimoto K, Kawaoka Y, Auewarakul P. Induction of TNF-alpha in human macrophages by avian and human influenza viruses. Arch Virol 155:1273-1279, 2010.
Chen Y, Zhong G, Wang G, Deng G, Li Y, Shi J, Zhang Z, Guan Y, Jiang Y, Bu Z, Kawaoka Y, Chen H. Dogs are highly susceptible to H5N1 avian influenza virus. Virology 405:15-19, 2010.
Iwai A, Shiozaki T, Kawai T, Akira S, Kawaoka Y, Takada A, Kida H, Miyazaki T. Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1. J Biol Chem 285:32064-32074, 2010.
Hatta Y, Hershberger K, Shinya K, Dubielzig RR, Hatta M, Kawaoka Y, Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog 6:e1001139, 2010.
Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathg. 6:e1001121, 2010.
Imai H, Shinya K, Takano R, Kiso M, Muramoto Y, Sakabe S, Murakami S, Ito M, Yamada S, Le MQ, Nidom CA, Sakai-Tagawa Y, Takahashi K, Omori Y, NodaT, Shimojima M, Kakugawa S, Goto H, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. The HA and NS genes of human H5N1 influenza A virus contribute to high virulence in ferrets. PLoS Pathog 6:e1001106, 2010.
Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. High genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J Virol 84:10918-10922, 2010.
Tamura D, Fujino M, Ozawa M, Iwatsuki-Horimoto K, Goto H, Sakai-Tagawa Y, Horimoto T, Nirasawa M, Kawaoka Y. Significance of seasonal influenza viruses in the stool of pediatric patients. Pediatr Infect Dis J 29:578-579, 2010.
Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, Katsura H, Kakugawa S, Le MQ, Yamashita M, Furuta Y, Ozawa M, Kawaoka Y. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 6:e1001079, 2010.
Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y. H5N1 influenza viruses from pigs in Indonesia. Emerg Inf Dis 16:1515-1523, 2010.
Le QM, Ito M, Muramoto Y, Hoang PVM, Vuong CD, Sakai-Tagawa Y, Kiso M, Takano R, Kawaoka Y. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans from 2003 to 2008 in Northern Vietnam. J Gen Virol 91: 2485 - 2490, 2010.
Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom CA, Lank SM, Wiseman RW, Bimber BN, O’Connor DH, Neumann G, Stewart LJ, Kawaoka Y. Biological and structural characterization of a host-adapting amino acid in influenza virus.PLoS Pathog 6:e1001034, 2010
Grandea III AG., Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui P-Y, Mitcham J, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M. Human antibodies reveal a protective epitope that is highly conserved among human and non-human influenza A viruses. Proc Natl Acad Sci U S A 107:12658-12663, 2010.
Sakai-Tagawa Y, Ozawa M, Tamura D, Le QM, Nidom CA, Sugaya N, Kawaoka Y. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol 48:2872-2877, 2010.
Matsuno K, Kishida N, Usami K, Igarashi M, Yoshida R, Nakayama E, Shimojima M, Feldmann H, Irimura T, Kawaoka Y, Takada A. Different potential of C-type lectin-mediated entry between Marburg virus strains. J Virol 84:5140-5147, 2010.
Jasenosky LD, Neumann G, Kawaoka Y. Minigenome-based reporter system suitable for high-throughput screening of compounds able to inhibit Ebolavirus replication and/or transcription. Antimicrob Agents Chemother 54:3007-3010, 2010.
Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G, Kawaoka Y. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc Natl Acad Sci U S A 107:4687-4692, 2010.
Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, Kawaoka Y. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 6:e1000786, 2010.
Noda T, Hagiwara K, Sagara H, Kawaoka Y. Characterization of the Ebola virus nucleoprotein-RNA complex. J Gen Virol91:1478-1483, 2010.
Shtanko O, Imai M, Goto H, Lukashevich IS, Neumann G, Watanabe T, Kawaoka Y. A role for the C terminus of Mopeia virus nucleoprotein in its incorporation into Z protein-induced virus-like particles. J Virol 84:5415-5422, 2010.
Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Kawaoka Y. A mutation in H5 haemagglutinin that conferred human receptor recognition is not maintained stably during duck passage. J Gen Virol 91:1461-1463, 2010.
Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, Kawaoka Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 107:882-887, 2010.
Kim JH, Hatta M, Watanabe S, Neumann G, Watanabe T, Kawaoka Y. Role of host-specific amino acids in the pathogenicity of avian H5N1 influenza viruses in mice. J Gen Virol 91:1284-1289, 2010.

2009

Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, Guan Y, Tian G, Li Y, Shi J, Liu L, Zeng X, Bu Z, Xia X, Kawaoka Y, Chen H. Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host.PLoS Pathog 5:e1000709, 2009.
Cilloniz C, Shinya K, Peng X, Korth MJ, Proll SC, Aicher LD, Carter VS, Chang JH, Kobasa D, Feldmann F, Strong JE, Feldmann H, Kawaoka Y, Katze MG. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 5(10):e1000604, 2009.
Kashima Y, Ikeda M, Itoh Y, Sakoda Y, Nagata T, Miyake T, Soda K, Ozaki H, Nakayama M, Shibuya H, Okamatsu M, Ishigaki H, Ishida H, Sawai T, Kawaoka Y, Kida H, Ogasawara K. Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines. Vaccine 27:7402-7408, 2009.
Takahashi T, Hashimoto A, Maruyama M, Ishida H, Kiso M, Kawaoka Y, Suzuki Y, Suzuki T. Identification of amino acid residues of influenza A virus H3 HA contributing to the recognition of molecular species of sialic acid. FEBS Lett 583:3171-3174, 2009.
Shinya K, Makino A, Ozawa M, Kim JH, Sakai-Tagawa Y, Ito M, Le QM, Kawaoka Y. Ostrich involvement in the selection of H5N1 influenza virus possessing mammalian-type amino acids in the PB2 protein. J Virol 83:13015-13018, 2009.
Victor ST, Lezhava A, Ishidao T, Endo R, Mitani Y, Kawaoka Y, Hayashizaki Y. Isothermal single nucleotide polymorphism genotyping and direct PCR from whole blood using a novel whole-blood lysis buffer. Mol Diagn Ther 13:383-387, 2009.
Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, Wentworth DE. Single Reaction Genomic Amplification Accelerates Sequencing and Vaccine Production for Classical and Swine Origin Human Influenza A Viruses. J Virol 83:10309-10313, 2009.
Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025, 2009.
WHO/OIE/FAO H5N1 Evolution Working Group. Continuing progress towards a unified nomenclature for the highly pathogenic H5N1 avian influenza viruses: divergence of clade 2.2 viruses. Influenza Other Respi Viruses 3:59-62, 2009.
Kakugawa S, Shimojima M, Neumann G, Goto H, Kawaoka Y. RuvB-like 2 protein is a suppressor of influenza A virus polymerases. J Virol 83:6429-6434, 2009.
Fujii K, Ozawa M, Iwatsuki-Horimoto K, Horimoto T, Kawaoka Y. The incorporation of influenza A virus genome Segments Does Not Absolutely Require Wild-Type Sequences. J Gen Virol 90:1734-1740, 2009.
Watanabe S, Watanabe T, Kawaoka Y. Influenza A virus lacking M2 protein as a live attenuated vaccine. J Virol 83:5947-5950, 2009.
Hatta M, Kohlmeier CK, Hatta Y, Ozawa M, Kawaoka Y. The region required for protein expression from the stop-start pentanucleotide in the M gene of influenza B virus. J Virol 83:5939-5942, 2009.
Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Tong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu XN, Bu Z, Kawaoka Y, Chen H. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5(5):1-11, 2009.
Takano R, Nidom CA, Kiso M, Muramoto Y, Yamada S, Shinya K, Sakai-Tagawa Y, Kawaoka Y. A comparison of the pathogenicity of avian and swine H5N1 influenza viruses in Indonesia. Arch Virol 154:677-681, 2009.
Tamura D, Mitamura K, Yamazaki M, Fujino M, Nirasawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Hiroi S, Takahashi K, Hatta M, Minagawa H, Kimura Y, Kaneda S, Sugita S, Horimoto T, Sugaya N, Kawaoka Y. Oseltamivir-Resistant Influenza A Viruses Circulating in Japan. J Clin Micro 47:1424-1427, 2009.
Le QM, Sakai-Tagawa Y, Ozawa M, Ito M, Kawaoka Y. Selection of H5N1 influenza virus PB2 during replication in humans. J Virol 83:5278-5281, 2009.
Neumann G, Watanabe S, Kawaoka Y. Characterization of Ebolavirus Regulatory Genomic Regions. Virus Res 144:1-7, 2009.
Li Z, Watanabe T, Hatta M, Watanabe S, Nanbo A, Ozawa M, Kakugawa S, Shimojima M, Yamada S, Neumann G, Kawaoka Y. Mutational analysis of conserved amino acids in the influenza A virus nucleoprotein. J Virol 83:4153-4162, 2009.
Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, Neumann G, Feldmann H, Kawaoka Y. Replication-Deficient Ebolavirus as a Vaccine Candidate. J Virol 83:3810-3805, 2009.
Fan S, Deng G, Song J, Tian G, Suo Y, Jiang Y, Guan Y, Bu Z, Kawaoka Y, Chen H. Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology 384:28-32, 2009.
Kakugawa S, Shimojima M, Goto H, Horimoto T, Oshimori N, Neumann G, Yamamoto T, Kawaoka Y. The Mitogen-activated protein kinase-activated kinase RSK2 plays a role in innate immune responses to influenza virus infection. J Virol 83:2510-2517, 2009.
Ozawa M, Maeda J, Iwatsuki-Horimoto K, Watanabe S, Goto H, Horimoto T, Kawaoka Y. Nucleotide sequence requirements at the 5' end of the influenza A virus M RNA segment for efficient virus replication. J Virol 83:3384-3388, 2009.
Marsolais D, Hahm B, Walsh KB, Edelmann KH, McGavern D, Hatta Y, Kawaoka Y, Rosen H, Oldstone MB. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci U S A106:1560-1565, 2009.
Watanabe T, Watanabe S, Shinya K, Kim JH, Hatta M, Kawaoka Y. Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. Proc Natl Acad Sci U S A 106:588-592, 2009.
Murakami S, Horimoto T, Mai le Q, Nidom CA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J Virol 82:10502-10509, 2009.
Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol83:2382-2385, 2009.
Makino A, Horimoto T, Kawaoka Y. Binding properties of GP1 protein of Borna disease virus. J Vet Med Sci 71:243-246, 2009.
Makino A, Kawaoka Y. Generation of vero cells expressing ebola virus glycoprotein. J Vet Med Sci 71:505-507, 2009.
Takano R, Nidom CA, Kiso M, Muramoto Y, Yamada S, Sakai-Tagawa Y, Macken C, Kawaoka Y. Phylogenetic characterization of H5N1 avian influenza viruses isolated in Indonesia from 2003-2007. Virology 390:13-21, 2009.
Fan S, Deng G, Song J, Tian G, Suo Y, Jiang Y, Guan Y, Bu Z, Kawaoka Y, Chen H. Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology 384:28-322, 2009.
Fan S, Gao Y, Shinya K, Li CK, Li Y, Shi J, Jiang Y, Suo Y, Tong T, Zhong G, Song J, Zhang Y, Tian G, Guan Y, Xu XN, Bu Z, Kawaoka Y, Chen H. Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathogens 5:1-11, 2009.
Takahashi T, Hashimoto A, Maruyama M, Ishida H, Kiso M, Kawaoka Y, Suzuki Y, Suzuki T. Identification of amino acid residues of influenza A virus H3 HA contributing to the recognition of molecular species of sialic acid. FEBS Lett 583:3171-31714, 2009.

2008

Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol 82:1605-1609, 2008.
Zhu Q, Yang H, Chen W, Cao W, Zhong G, Jiao P, Deng G, Yu K, Yang C, Bu Z, Kawaoka Y, Chen H. A naturally occurring deletion in its NS gene contributes to the attenuation of an H5N1 swine influenza virus in chickens. J Virol 82:220-228, 2008.
Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26:562-572, 2008.
Watanabe T, Watanabe S, Kim JH, Hatta M, Kawaoka Y. A novel approach to the development of effective H5N1 influenza A virus vaccines: the use of M2 cytoplasmic tail mutants. J Virol 82:2486-2492, 2008.
Halfmann P, Kim JH, Ebihara H, Noda T, Neumann G, Feldmann H, Kawaoka Y. Generation of biologically contained Ebola viruses. Proc Natl Acad Sci USA 105: 1129-1133, 2008.
Yamayoshi S, Noda T, Ebihara H, Goto H, Morikawa Y, Lukashevich IS, Neumann G, Feldmann H, Kawaoka Y. Ebola virus matrix VP40 protein uses the COPII transport system for its intracellular transport. Cell Host&Microbe 3:168-177, 2008.
Iwatsuki-Horimoto K, Hatta Y, Hatta M, Muramoto Y, Chen H, Kawaoka Y, Horimoto T. Limited compatibility between the RNA polymerase components of influenza virus type A and B. Virus Res 135:161-165, 2008.
Sakabe S, Sakoda Y, Haraguchi Y, Isoda N, Soda K, Takakuwa H, Saijo K, Sawata A, Kume K, Hagiwara J, Tuchiya K, Lin Z, Sakamoto R, Imamura T, Sasaki T, Kokumai N, Kawaoka Y, Kida H. A vaccine prepared from a non-pathogenic H7N7 virus isolated from natural reservoir conferred protective immunity against the challenge with lethal dose of highly pathogenic avian influenza virus in chickens. Vaccine 26:2127-2134, 2008.
Sawai T, Itoh Y, Ozaki H, Isoda N, Okamoto K, Kashima Y, Kawaoka Y, Takeuchi Y, Kida H, Ogasawara K. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin. Immunology 124:155-165, 2008.
Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, Mitamura K. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 47:339-345, 2008.
Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893, 2008.
Murakami S, Iwasa A, Iwatsuki-Horimoto K, Ito M, Kiso M, Kida H, Takada A, Nidom CA, Mai le Q, Yamada S, Imai H, Sakai-Tagawa Y, Kawaoka Y, Horimoto T. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine26:6398-6404, 2008.
Marsolais D, Hahm B, Edelmann KH, Walsh KB, Guerrero M, Hatta Y, Kawaoka Y, Roberts E, Oldstone MB, Rosen H. Local not systemic modulation of dendritic cell S1P receptors in lung blunts virus-specific immune responses to influenza. Mol Pharmacol 74:896-903, 2008.
WHO/OIE/FAO H5N1 Evolution Working Group. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis. 14:e1, 2008.
Jia B, Shi J, Li Y, Shinya K, Muramoto Y, Zeng X, Tian G, Kawaoka Y, Chen H. Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons. Arch Virol 153:1821-1826, 2008.
Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y. Compatibility among polymerase subunit proteins is a restricting factor in reassortment between equine H7N7 and human H3N2 influenza viruses. J Virol. 82:11880-11888, 2008.

2007

Kobasa D, Jones, SM, Shinya K, Kash JC, Copps J, Ebihara H, Hatta Y, Kim JH, Halfmann P, Hatta M, Feldmann F, Alimonti JB, Fernando L, Li Y, Katze MG, Feldmann H, Kawaoka Y. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:23, 2007.
Takada A, Ebiharab H, Jones S, Feldmannd H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25:993-999, 2007.
Ozawa M, Fujii K, Muramoto Y, Yamada S, Yamayoshi S, Takada A, Goto H, Horimoto T, Kawaoka Y. Contributions of two nuclear localization signals of influenza A virus nucleoprotein to viral replication. J Virol 81:30-41, 2007.
Neumann G, Geisbert TW, Ebihara H, Geisbert JB, Daddario-Dicaprio KM, Feldmann H, Kawaoka Y. Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Critical for Ebola Virus Replication in Nonhuman Primates. J Virol 81, 2995-2998, 2007.
Noda T, Watanabe S, Sagara H, Kawaoka Y. Mapping of theVP40-binding regions of the Nucleoprotein of Ebola virus. J Virol81, 3554-3562, 2007.
Garulli B, Meola M, Stillitano MG, Kawaoka Y, Castrucci MR. Efficient vagina-to-lower respiratory tract immune trafficking in a murine model of influenza A virus infection. Virology 361, 274-282, 2007.
Kurosaki Y, Takada A, Ebihara H, Grolla A, Kamo N, Feldmann H, Kawaoka Y, Yasda J. Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification. J Virol Methods 141, 78-83, 2007.
Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, Kawakami C, Kiso M, Ito M, Hatakeyama S, Kawaoka Y. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis44:197-202, 2007.
Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. Emergence of Influenza B Viruses with Reduced Sensitivity to Neuraminidase Inhibitors. JAMA 297: 1435-1442, 2007.
Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J Virol 81:4895-4899, 2007.
Horimoto T, Murakami S, Muramoto Y, Yamada S, Fujii K, Kiso M, Iwatsuki-Horimoto K, Kino Y, Kawaoka Y. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366:23-27, 2007.
Ozawa M, Goto H, Horimoto T, Kawaoka Y. An adenoviral vector-mediated reverse genetics system for influenza A virus generation. J Virol 81:9556-9559, 2007.
Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice PLoS Pathog 3:1374-1379, 2007.
Rigoni M, Shinya K, Toffan A, Milani A, Bettini F, Kawaoka Y, Cattoli G, Capua I. Pneumo- and eurotropism of avian origin Italian highly pathogenic avian influenza H7N1 isolates in experimentally infected mice. Virology 364, 28-35, 2007.
Guo CT, Takahashi N, Yagi H, Kato K, Takahashi T, Yi SQ, Chen Y, Ito T, Otsuki K, Kida H, Kawaoka Y, Hidari KI, Miyamoto D, Suzuki T, Suzuki Y. The quail and chicken intestine have sialyl-galactose sugar chains responsible for the binding of influenza A viruses to human type receptors. Glycobiology 17, 713-724, 2007.
Sawada T, Hashimoto T, Nakano H, Suzuki T, Suzuki Y, Kawaoka Y, Ishida H, Kiso M. Influenza viral hemagglutinin complicated shape is advantageous to its binding affinity for sialosaccharide receptor. Biochem Biophys Res Commun 355:6-9, 2007.
Shinya K, Watanabe S, Ito T, Kasai N, Kawaoka Y. Adaptation of an H7N7 equine influenza A virus in mice. J Gen Virol 88, 547-552, 2007.
Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y. Epitopes required for antibodydependentenhancement of Ebola virus infection. J Infect Dis 196 Suppl 2:S347-356, 2007.
Ebihara H, Theriault S, Neumann G, Alimonti JB, Geisbert JB, Hensley LE, Groseth A, Jones SM, Geisbert TW, Kawaoka Y, Feldmann H. in vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.J Infect Dis 196 Suppl 2:S313-322, 2007.
Yamayoshi S, Kawaoka Y. Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. J Infect Dis 196 Suppl 2:S291-295, 2007.
Watanabe S, Noda T, Halfmann P, Jasenosky L, Kawaoka Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect Dis 196 Suppl 2:S284-290, 2007.
Shimojima M, Ikeda Y, Kawaoka Y. The mechanism of Axl-mediated Ebola virus infection. J Infect Dis 196 Suppl 2:S259-263, 2007.
Noda T, Halfmann P, Sagara H, Kawaoka Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J Infect Dis 196 Suppl 2:S247-250, 2007.
Jiao P, Tian G, Li Y, Deng G, Jiang Y, Liu C, Liu W, Bu Z, Kawaoka Y, Chen H. A single amino acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J Virol 82:1146-1154, 2007.
Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, Kozaki S, Igarashi O, Kiyono H. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 204:2789-2796, 2007.

2006

Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M, Kawaoka Y. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24:3669-3676, 2006.
Muramoto Y, Ozaki H, Takada A, Park CH, Sunden Y, Umemura T, Kawaoka Y, Matsuda H, Kida H. Highly pathogenic H5N1 influenza virus causes coagulopathy in chickens. Microbiol Immunol 50:73-81, 2006.
Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J. Cellular factors required for Lassa virus budding. J Virol 80:4191-4195, 2006.
Watanabe S, Noda T, Kawaoka Y. Functional mapping of the nucleoprotein of Ebola virus. J Virol 80:3743-3751, 2006.
Muramoto Y, Takada A, Fujii K, Noda T, Iwatsuki-Horimoto K, Watanabe S, Horimoto T, Kida H, Kawaoka Y. Hierarchy among vRNA segments in their role in vRNA incorporation into influenza A virions. J Virol 80:2318-25, 2006.
Bar S, Takada A, Kawaoka Y, Alizon M. Detection of cell-cell fusion mediated by the Ebola virus glycoproteins. J Virol 80:2815-22, 2006.
Iwatsuki-Horimoto K, Horimoto T, Noda T, Kiso M, Maeda J, Watanabe S, Muramoto Y, Fujii K, Kawaoka Y. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 80:5233-5240, 2006.
Chen H, Li Y, Li Z, Shi J, Shinya K, Deng G, Qi Q, Tian G, Fan S, Zhao H, Sun Y, Kawaoka Y. Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China. J Virol 80:5976-5983, 2006.
Muramoto Y, Le TQ, Phuong LS, Nguyen T, Nguyen TH, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Horimoto T, Kida H, Kawaoka Y. Molecular characterization of the hemagglutinin and neuraminidase genes of H5N1 influenza A viruses isolated from poultry in Vietnam from 2004 to 2005. J Vet Med Sci 68:527-531, 2006.
Kogure T, Suzuki T, Takahashi T, Miyamoto D, Hidari KI, Guo CT, Ito T, Kawaoka Y, Suzuki Y. Human trachea primary epithelial cells express both sialyl(alpha2-3)Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl(α2-6)Gal receptor for human influenza viruses. Glycoconj J 23:101-106, 2006.
Noda T, Sagara H, Yen A, Takada A, Kida A, Cheng RH, Kawaoka Y. Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 439:490-492, 2006.
Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. Nature 440:435-436, 2006.
Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S, Bray M, Feldmann H, Kawaoka Y. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2: 705-711, 2006.
Shimojima M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, Jones S, Feldmann H, Kawaoka Y. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 80: 10109-10116, 2006.
Noda T, Ebihara H, Muramoto Y, Fujii K, Takada A, Sagara H, Kim JH, Kida H, Feldmann H, Kawaoka Y. Assembly and budding of Ebolavirus. PLoS Pathog 2:864-872, 2006.
Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Kiso K, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ, Kawaoka Y. Hemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382, 2006.
Co DO, Hogan LH, Karman J, Heninger E, Vang S, Wells K, Kawaoka Y, Sandor M. Interactions between T cells responding to concurrent mycobacterial and influenza infections. J Immunol 177:8456-8465, 2006.

2005

Shinya K, Suto A, Kawakami M, Sakamoto H, Umemura T, Kawaoka Y, Kasai N, Ito T. Neurovirulence of H7N7 influenza A virus: brain stem encephalitis accompanied with aspiration pneumonia in mice. Arch Virol 150:1653-1660, 2005.
Noda T, Aoyama K, Sagara H, Kida H, Kawaoka Y. Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography. J Vet Med Sci 67:325-328, 2005.
Mase M, Tsukamoto K, Imada T, Imai K, Tanimura N, Nakamura K, Yamamoto Y, Hitomi T, Kira T, Nakai T, Kiso M, Horimoto T, Kawaoka Y, Yamaguchi S. Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. Virology 332:167-176, 2005.
Fujii K, Fujii Y, Noda T, Muramoto Y, Watanabe T, Takada A, Goto H, Horimoto T, Kawaoka Y. The importance of both the coding and segment-specific noncoding regions of the influenza A virus NS segment for its efficient incorporation into virions. J Virol 79:3766-3774, 2005.
Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, Kawaoka Y. Live bivalent vaccine for parainfluenza and influenza virus infections. J Virol 79:6674-6679, 2005.
Shinya K, Hatta M, Yamada S, Takada A, Watanabe S, Halfmann P, Horimoto T, Neumann G, Lim W, Guan Y, Peiris M, Suzuki T, Suzuki Y, Kawaoka Y. Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol 79:9926-9932, 2005.
Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, Mitamura K, Sugaya N, Suzuki Y, Kawaoka Y. Enhanced expression of an α2,6-linked sialic acid on MDCK cells improves the isolation of human influenza viruses and the evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Micro 43:4139-4146, 2005.
Neumann G, Ebihara H, Takada A, Noda T, Kobasa D, Jasenosky LD, Watanabe S, Kim JH, Feldmann H, Kawaoka Y. The Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol 79:10300-10307, 2005.
Mase M, Eto M, Tanimura N, Imai K, Tsukamoto K, Horimoto T, Kawaoka Y, Yamaguchi S. Isolation of a genotypically unique H5N1 influenza virus from duck meat imported into Japan from China. Virology 339:101-109, 2005.
Suzuki T, Takahashi T, Guo C-T, K.I.-P. J Hidari, Miyamoto D, Goto H, Kawaoka Y, Suzuki Y. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol 79: 11705-11715, 2005.
Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci 102:16825-16829, 2005.
Le QM, Kiso M, Someya K, Sakai YT, NguyenTH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. Emergence of an oseltamivir-resistant H5N1 influenza A virus. Nature437:1108, 2005.

2004

Kondo T, McGregor M, Chu O, Chen D, Horimoto T, Kawaoka Y. Protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection. Virology 318:414-419, 2004.
Watanabe S, Watanabe T, Noda T, Takada A, Feldmann H, Jasenosky LD, Kawaoka Y. Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J Virol 78: 999-1005, 2004.
Maeda Y, Goto H, Horimito T, Takada A, Kawaoka Y. Biological significance of the U residue at the -3 position of the mRNA sequences of influenza A viral segments PB1 and NA. Virus Res 100:153-157, 2004.
Takada A, Fujioka K, Tsuiji M, Morikawa A, Higashi N, Ebihara H, Kobasa D, Feldmann H, Irimura T, Kawaoka Y. A human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 78:2943-2947, 2004.
Garulli B, Kawaoka Y, Castrucci MR. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol 78:1020-1025, 2004.
Horimoto T, Takada A, Iwatsuki-Horimoto K, Kawaoka Y. A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine model. Vaccine 22:2244-2247, 2004.
Horimoto H, Fukuda N, Iwatsuki-Horimoto K, Guan Y, Lim W5, Peiris M, Sugii S, Odagiri T, Tashiro M, Kawaoka Y. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Sci 66:303-305, 2004.
Iwatsuki-Horimoto K, Kanazawa R, Sugii S, Kawaoka Y, Horimoto T. The index influenza A virus subtype H5N1 isolated from a human in 1997 differs in its receptor binding properties from a virulent avian influenza virus. J Gen Virol 85:1001-1005, 2004.
Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 320:258-266, 2004.
Shinya K, Fujii Y, Ito H, Ito T, Kawaoka Y. Characterization of a neuraminidase-deficient influenza A virus as a potential gene delivery vector and a live vaccine. J Virol 78:3083-3088, 2004.
Hatta M, Goto H, Kawaoka Y. Influenza B virus requires BM2 protein for replication. J Virol 78: 5576-5583, 2004.
Barman S, Adhikary L, Chakrabarti AK, Bernas C, Kawaoka Y, Nayak DP. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza A virus neuraminidase in raft association and virus budding. J Virol 78: 5258-5269, 2004.
Iwatsuki-Horimoto K, Horimoto T, Fujii Y, Kawaoka Y. Generation of influenza A virus NS2(NEP) mutants with an altered nuclear export signal sequence. J Virol 78:10149-10155, 2004.
Horimoto T, Iwatsuki-Horimoto K, Hatta M, Kawaoka Y. Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components. Microbes and Infection 6:579-583, 2004.
Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765, 2004.
Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, Usui T, Murata T, Maeda Y, Watanabe S, Suresh M, Suzuki T, Suzuki Y, Feldmann H, Kawaoka Y. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707, 2004.
Theriault S, Groseth A, Neumann G, Kawaoka Y, Feldmann H. Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res 106:43-50, 2004

2003

Takada A, Feldmann H, Stroeher U, Bray M, Watanabe S, Ito H, Mcgregor M, Kawaoka Y. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level using recombinant vesicular stomatitis viruses. J Virol 77:1069-1074, 2003.
Mueller SN, Jones CM, Chen W, Kawaoka Y, Castrucci MR, Heath WR, Carbone FR. The early expression of glycoprotein B from herpes simplex virus can be detected by antigen-specific CD8+ T cells. J Virol 77: 2445-2451, 2003.
Barman S, Adhikary L, Kawaoka Y, Nayak DP. Influenza A virus hemagglutinin containing basolateral localization signal does not alter the apical budding of a recombinant influenza A virus in polarized MDCK cells. Virology 305:138-52, 2003.
Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Inf Dis 188:57-61, 2003.
Fujii Y, Goto H, Watanabe T, Yoshida T, Kawaoka Y. Selective incorporation of influenza virus RNA segments into virions. Proc Natl Acad Sci USA 100:2002-2007, 2003.
Ogino M, Ebihara H, Lee BH, Araki K, Lundkvist A, Kawaoka Y, Yoshimatsu K, Arikawa J. Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul Virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol 10:154-160, 2003.
Hatta M, Kawaoka Y. The NB protein of influenza B virus is not necessary for virus replication in vitro. J Virol 77:6050-6054, 2003.
Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 77:7539-7544, 2003.
Horimoto T, Takada A, Iwatsuki-Horimoto K, Hatta M, Goto H, Kawaoka Y. Generation of influenza A viruses with chimeric (type A/B) hemagglutinins. J Virol 77:8031-8038, 2003.
Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin- inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218, 2003.
Watanabe T, Watanabe A, Noda T, Fujii Y, Kawaoka Y. Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. J Virol 77:10575-10583, 2003.
Yasuda J, Nakao M, Kawaoka Y, Shida H. Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol 77:9987-9992, 2003.

2002

Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 76:406-410, 2002.
Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 76:767-773, 2002.
Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 76:4855-4865, 2002.
Ito T, Kobayashi Y, Morita T, Horimoto T, Kawaoka Y. Virulent influenza A viruses induce apoptosis in chickens. Virus Res84:27-35, 2002.
Hatta M, Halfmann P, Wells K, Kawaoka Y. Human influenza A viral genes responsible for the restriction of its replication in duck intestine. Virology 295:250-255, 2002.
Watanabe T, Watanabe S, Kida H, Kawaoka Y. Influenza A virus with defective M2 ion channel activity as a live vaccine.Virology 299:266-270, 2002.
Shengqing Y, Kishida N, Ito H, Kida H, Otsuki K, Kawaoka Y, Ito T. Generation of velogenic Newcastle disease viruses from a nonpathogenic waterfowl isolate by passaging in chickens. Virology 301:206-211, 2002.

2001

Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 75:1576-1580, 2001.
Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol75:2324-2330, 2001.
Ito T, Goto H, Yamamoto E, Tanaka H, Takeuchi M, Kuwayama M, Kawaoka Y, Otsuki K. Generation of a highly pathogenic avian influenza A virus from an avirulent field isolate by passaging in chickens. J Virol 75:4439-4443, 2001.
Hughes MT, McGregor M, Suzuki T, Suzuki Y, Kawaoka Y. Adaptation of influenza A viruses to cells expressing low levels of sialic acid leads to loss of neuraminidase activity. J Virol 75:3766-3770, 2001.
Mase M, Imada T, Sanada Y, Etoh M, Sanada Y, Tsukamoto K, Kawaoka Y, Yamaguchi S. Imported parakeets harbor H9N2 influenza A viruses that are genetically closely related to those transmitted to humans in Hong Kong. J Virol 75:3490-3494, 2001.
Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75:5205-5214, 2001.
Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 75:5656-5662, 2001.
Schultz-Cherry S, Dybdahl-Sissoko N, Neumann G, Kawaoka Y, Hinshaw VS. Influenza virus NS1 protein induces apoptosis in cultured cells. J Virol 75: 7875-7881, 2001.
Goto H, Wells K, Takada A, Kawaoka Y. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. J Virol 75:9297-9301, 2001.
Kobasa D, Wells K, KawaokaY. Amino acids responsible for the absolute sialidase activity of the influenza A virus neuraminidase: relationship to growth in duck intestine. J Virol 75:11773-11780, 2001.
Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science298:1840-1842, 2001.

2000

Neumann G, Watanabe T, Kawaoka Y. Plasmid-driven formation of influenza virus-like particles. J Virol 74:547-51, 2000.
Masuda H, Suzuki T, Sugiyama Y, Horiike G, Murakami K, Miyamoto D, Jwa Hidari KI, Ito T, Kida H, Kiso M, Fukunaga K, Ohuchi M, Toyoda T, Ishihama A, Kawaoka Y, Suzuki Y. Substitution of amino acid residue in influenza A virus hemagglutinin affects recognition of sialyl-oligosaccharides containing N-glycolylneuraminic acid FEBS Lett 464:71-4, 1999.
Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. "Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 267:310-317, 2000.
Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108-6113, 2000.
Hatta M, Asano Y, Masunaga K, Ito T, Okazaki K, Toyoda T, Kawaoka Y, Ishihama A, Kida H. Epitope mapping of the influenza A virus RNA polymerase PA using monoclonal antibodies. Arch Virol 145:957-964, 2000.
Mitnaul LJ, Matrosovich MN, Castrucci MR, Tuzikov AB, Bovin NV, Kobasa D, Kawaoka Y. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 74:6015-6020, 2000.
Hughes MT, Matrosovich M, Rodgers ME, McGregor M, Kawaoka Y. Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice. J Virol 74:5206-5212, 2000.
Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Cox N, Castrucci M, Donatelli I, Kawaoka Y. Alterations of receptor-binding properties of H1, H2 and H3 avian influenza virus hemagglutinins upon introduction into mammals. J Virol74:8502-8512, 2000.
Ito T, Suzuki Y, Suzuki T, Takada A, Horimoto T, Wells K, Kida H, Otsuki K, Kiso M, Ishida H, Kawaoka Y. Recognition of N-glycolylneuraminic acid linked to galactose by the α2,3 linkage is associated with intestinal replication of influenza A virus in ducks. J Virol 74:9300-9305, 2000.
Watanabe S, Takada A, Watanabe T, Ito H, Kida H, Kawaoka Y. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol 74:10194-10201, 2000.
Takada A, Watanabe S, Ito H, Okazaki K, Kida H, Kawaoka Y. Downregulation of β1 integrins by Ebola virus glycoprotein: Implication for virus entry. Virology 278:20-26, 2000.
Neumann G, Hughes MT, Kawaoka Y. Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J 19:6751-6758, 2000.
Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice. Nature Medicine 6:1187-1190, 2000.
Suzuki Y, Ito T, Suzuki T, Holland Jr, RE, Chambers TM, Kiso M, Ishida H, Kawaoka Y. Sialic acid species as a determinant of the host range of influenza A viruses. J Virol 74:11825-31, 2000.
Hatta M, Asano Y, Masunaga K, Ito T, Okazaki K, Toyoda T, Kawaoka Y, Ishihama A, Kida H. Mapping of functional domains on the influenza A virus RNA polymerase PB2 molecule using monoclonal antibodies. Arch Virol 145: 1947-1961, 2000.

総説

2023

Neumann G, Kawaoka Y. The COVID-19 Pandemic-A Potential Role for Antivirals in Mitigating Pandemics. Viruses 15(2):303. doi: 10.3390/v15020303. 2023.
Neumann G, Kawaoka Y. Which Virus Will Cause the Next Pandemic? Viruses 15(1):199 doi: 10.3390/v15010199. 2023.

2022

Imai M, Takada K, Kawaoka Y. Receptor-Binding Specificity of Influenza Viruses. Methods Mol Biol 2556:79-96. doi: 10.1007/978-1-0716-2635-1_8. 2022.
DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet LM, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara VV, Ellebedy A, Fabrizio TP, Ferrari G, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O'Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi PY, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turner SA, Vakaki MA, van Bakel H, VanBlargan LA, Vincent LR, Wallace ZS, Wang L, Wang M, Wang P, Wang W, Weaver SC, Webby RJ, Weiss CD, Wentworth DE, Weston SM, Whelan SPJ, Whitener BM, Wilks SH, Xie X, Ying B, Yoon H, Zhou B, Hertz T, Smith DJ, Diamond MS, Post DJ, 25-. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. doi: 10.1038/s41586-022-04690-5. 2022.
Neumann G, Kawaoka Y. Seasonality of influenza and other respiratory viruses. EMBO Mol Med e15352, 2022.
Uraki R, Kawaoka Y. Host glycolipids in SARS-CoV-2 entry. Nat Chem Biol 18(1):6-7, 2022.

2021

Neumann G, Kawaoka Y. Quo Vadis Influenza? China CDC Wkly 3(49):1046-1048, 2021.
Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, Cameron MJ, Friemann MB, Neumann G, Kawaoka Y, Kelvin AA, Ross TM, Schultz-Cherry S, Mastro TD, Priddy FH, Moore KA, Ostrowsky JT, Osterholm MT, Goudsmit J. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med 13(579):eabd1525, 2021.

2020

Yamayoshi S, Kawaoka Y. Emergence of SARS-CoV-2 and its outlook. Glob Health Med 2(1):1-2, 2020.
Neumann G, Kawaoka Y. Optimization of animal models to better predict influenza vaccine efficacy (VA). Vaccine 38:2749-2750, 2020.
Yamaji R, Saad MD, Davis CT, Swayne DE, Wang D, Wong FYK, McCauley JW, Peiris JSM, Webby RJ, Fouchier RAM, Kawaoka Y, Zhang W. Pandemic potential of highly pathogenic avian influenza clade 2.3.4.4 A(H5) viruses. Rev Med Virol 30:e2099, 2020.
Watanabe T, Kawaoka Y. Villains or heroes? The raison d'être of viruses. Clin Transl Immunol 9:e01114, 2020.
Yamayoshi S, Kawaoka Y. Uncovering the Anti-Ebola Repertome. Cell Host Microbe 27:163-165, 2020.

2019

Watanabe T, Suzuki N, Tomonaga K, Sawa H, Matsuura Y, Kawaguchi Y, Takahashi H, Nagasaki K, Kawaoka Y. Neo-virology: The raison d'etre of viruses. Virus Res 274:197751, 2019.
Neumann G, Kawaoka Y. Predicting the Next Influenza Pandemics. J Infect Dis S14-S20, 2019.
Yamayoshi S, Kawaoka Y. Host protein mimics viral protein to hinder infection by Ebola virus. Nature 566:190-191, 2019.
Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nat Med 25:212-220, 2019.
Nanbo A, Kawaoka Y. The Molecular Mechanism of Externalization of Phosphatidylserine on the Surface of Ebola Virus Particles. DNA Cell Biol 38:115-120, 2019.

2018

Neumann G, Fan S, Kawaoka Y. Selection of Antigenically Advanced Variants of Influenza Viruses. Methods Mol Bio. 1836:461-486, 2018.

2017

Watanabe T, Imai M, Kawaoka Y. NS1 is the fluid for “flu-transmission”. Proc Natl Acad Sci U S A. 14:11012-11014, 2017
Eisfeld AJ, Kawaoka Y. Calculated risk: a new single-nucleotide polymorphism linked to severe influenza disease. Nat Med. 223:911-912, 2017.
Kolesnikova L, Nanbo A, Becker S, Kawaoka Y. Inside the Cell: Assembly of Filoviruses. Curr Top Microbiol Immunol. 411:353-380, 2017.
Yamayoshi S, Kawaoka Y. Ebolavirus's Foibles. Cell. 2017 169:773-775, 2017.

2015

Watanabe T, Kawaoka Y. Influenza virus-host interactomes as a basis for antiviral drug development. Curr Opin Virol. 14:71-78, 2015.
Neumann G, Kawaoka Y. Transmission of influenza A viruses. Virology 480:234-246, 2015.
Eisfeld AJ, Neumann G, Kawaoka Y. At the centre: influenza A virus ribonucleoproteins. Nat Rev Microbiol 13:28-41, 2015.

2014

Halfmann P, Neumann G, Feldmann H, Kawaoka Y. Ebola Conquers West Africa - More to Come? EBioMedicin. 1:2-3, 2014.
Watanabe T, Watanabe S, Maher EA, Neumann G, Kawaoka Y. Pandemic potential of avian influenza A(H7N9) viruses Trends Microbiol 22:623-631, 2014.
Eisfeld AJ, Neumann G, Kawaoka Y. Influenza A virus isolation, culture and identification. Nature Protocol 9:2663-2681, 2014.
Herfst S, Imai M, Kawaoka Y, Fouchier RA. Avian Influenza Virus Transmission to Mammals. Curr Top Microbiol Immunol385:137-155, 2014.

2013

Imai M, Herfst S, Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, Fouchier RA, Kawaoka Y. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178: 15-20, 2013.
Ozawa M, Kawaoka Y. Cross talk between animal and human influenza viruses. Annu. Rev. Anim. Biosci. 1:21-42, 2013.

2012

Neumann G, Macken CA, Karasin AI, Fouchier RA, Kawaoka Y. Egyptian H5N1 Influenza Viruses-Cause for Concern? PLoS Pathog 8:e10029322012, 2012.
Fouchier RA, García-Sastre A, Kawaoka Y. The Pause on Avian H5N1 Influenza Virus Transmission Research Should Be Ended.mBio. 3(5). 2012.
Kawaoka Y. H5N1: Flu transmission work is urgent. Nature 482:7384, 2012.
Noda T, Kawaoka Y. Packaging of influenza virus genome: Robustness of selection. Proc Natl Acad Sci U S A. 109:8797-8798, 2012.
Neumann G, Ozawa M, Kawaoka Y. Reverse genetics of influenza viruses. Methods Mol Biol 865:193-206, 2012.
Kawaoka Y, Neumann G. Influenza viruses: An introduction. Methods Mol Biol 865:1-9, 2012.
Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opin Virol2:160-167, 2012.

2011

Ozawa M, Kawaoka Y. Taming influenza viruses. Virus Res 162:8-11, 2011.
Fukuyama S, Kawaoka Y. The pathogenesis of influenza virus infections: the contributions of virus and host factors. Curr Opin Immunol. 23:481-486, 2011.
Neumann G, Kawaoka Y. The first influenza pandemic of the new millennium. Influenza Other Respi Viruses 3:157-166, 2011.
Watanabe T, Kawaoka Y. Pathogenesis of the 1918 pandemic influenza virus. PLoS Pathog 7:e1001218, 2011.

2010

Noda T, Kawaoka Y. Structure of influenza virus ribonucleoprotein complexes and their packaging into virions. Rev Med Virol20:380-391, 2010.
Horimoto T, Kawaoka Y. Pandemic Influenza. Open Antimicro Agents J2: 9-14, 2010.
Watanabe T, Watanabe S, Kawaoka Y. Cellular networks involved in the influenza virus life cycle. Cell Host Microbe 7:427-439, 2010.
Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 20:51-61, 2010.
Shinya K, Makino A, Kawaoka Y. Emerging and reemerging influenza virus infections. Vet Pathol 47:53-57, 2010.

2009

Horimoto T, Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol 333:165-176, 2009.
Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of H1N1 influenza virus. Nature 459:931-939, 2009.
Kawaoka Y, Naiki M. Chemical structure of antibodies. In: Immunology in Veterinary Science. Izawa H,

2008

Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Highly pathogenic H5N1 influenza virus infection in humans. Lancet 371:1464-1475, 2008.
Neumann G, Horimoto T, Kawaoka Y. Reverse Genetics of Influenza Viruses - Applications in Research and Vaccine Design. In: Avian Influenza. Monogr Virol. Klenk H-D, Matrosovich MN, Stech J, eds. Karger, vol 27, pp.118-133, 2008.
de Wit E, Kawaoka Y, de Jong MD, Fouchier RA. Pathogenicity of highly pathogenic avian influenza virus n mammals. VaccineSuppl 4:D54-58, 2008.

2007

Neumann G, Kawaoka Y. Influenza viruses. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd: Chichester. http://www.els.net/[doi:10.1002/9780470015902.a0001031.pub2], 2007.
Wright PF, Neumann G, Kawaoka Y. Orthomyxoviruses. In: Fields Virology. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, 2007. Chapter 48, pp. 1691-1740.
Gabriele Neumann, Kyoko Shinya, Yoshihiro Kawaoka. Molecular pathogenesis of H5N1 influenza virus infections. Antiviral Therapy 12:617-626, 2007.

2006

Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis12:881-886, 2006.
Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol Med 12:506-154, 2006.
Neumann G, Kawaoka Y. Influenza Epidemics. In: ENCYCLOPEDIA OF LIFE SCIENCES. John Wiley & Sons, Ltd: Chichester. http://www.els.net/ [doi:10.1002/9780970015902.a0002241.pub2], 2006.

2005

Matrosovich MN, Klenk, HD, Kawaoka Y. Receptor specificity, host-range, and pathogenicity of influenza viruses. In: Influenza Virology Current Topics, Kawaoka ed., Horison press. p.95-137, 2005
Ebihara H, Groseth A, Neumann G, Kawaoka Y, Feldmann H. The role of reverse genetics systems in studying viral hemorrhagic fevers. Thromb Haemost, 94:240-253, 2005.
Parrish C, Kawaoka Y. The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu. Rev. Microbiol 59:553-86, 2005.
Kawaoka Y. How Ebola virus infects cells. New Eng J Med 352:2645-2646, 2005.
Horimoto T, Kawaoka Y. Influenza: Lessons from past pandemics, warnings from current incidents. Nature Rev Microbiol8:591-600, 2005.

2004

Neumann G, Noda T, Takada A, Jasenosky LD, Kawaoka Y. Roles of filovirus matrix- and glycoproteins in the viral life cycle. In:Ebola and Marburg Viruses: Molecular and Cellular Biology, Feldmann and Klenk, Eds., Horizon Bioscience, Wymondham, U.K. pp 137-179, 2004.
Neumann G, Kawaoka, Y. Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. In: Biology of Negative Strand RNA Viruses: The Power of Reverse Genetics, Kawaoka ed., Springer-Verlag, Heidelberg. Curr Top Microbiol Immunol 283:43-60, 2004.
Neumann G, Brownlee G, Fodor E, Kawaoka Y., Orthomyxovirus replication, transcription, and polyadenylation. In: Biology of Negative Strand RNA Viruses: The Power of Reverse Genetics, Kawaoka ed., Springer-Verlag, Heidelberg. Curr Top Microbiol Immunol 283:121-143, 2004.
Jasenosky LD, Kawaoka Y. Filovirus budding. Virus Res 106:181-188, 2004.

2003

Neumann G, Hatta M, Kawaoka Y. Reverse genetics for the control of avian influenza. Avian Dis 47(3 Suppl):882-887, 2003.
Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications.Rev Med Virol 13:387-398, 2003.

2002

Neumann G, Kawaoka Y. Generation of influenza A virus from cloned cDNAs - historical perspective and outlook for the new millennium. Rev Med Virol 12:13-30, 2002.
Neumann G, Kawaoka Y. Synthesis of influenza virus: new impetus from an old enzyme, RNA polymerase I. Virus Res 82:153-158, 2002.
Hatta M, Kawaoka Y. Continued pandemic threat posed by avian influenza A viruses in Hong Kong. Trends Microbiol 10:340-344, 2002.
Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned? J Gen Virol 83:2635-2662, 2002.

2001

Kawaoka Y. Influenza viruses, Encyclopedia of Life Sciences, Nature Publishing Group, 2001, www.els.net.
Kawaoka Y. Influenza epidemics, Encyclopedia of Life Sciences, Nature Publishing Group, 2001, www.els.net.
Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza viruses. Clin Microbiol Rev 14:129-49, 2001.
Neumann G, Kawaoka Y. Reverse genetics of influenza virus. Virology 287:243-250, 2001.
Suzuki Y, Ito T, Suzuki T, Miyamoto D, Kazuya I.-P. J. Hidari, Guo C.-T, Kida H, Webster R.G, Chambers T.M, Kawaoka Y. Sialyl sugar chains as receptors and determinants of host range of influenza A viruses. In Options for the Control of Influenza IVpp521-525, 2001.
Neumann G, Kawaoka Y. Genetic approach to studying influenza pathogenesis. In Options for the Control of Influenza IVpp587-590, 2001.
Goto H, Kawaoka Y. Role of plasminogen-binding NA in influenza pathogenicity: knockout of plasminogen binding activity by reverse genetics. In Options for the Control of Influenza IV pp591-594, 2001.
Hatta M, Halfmann P, Wells K, Kawaoka Y. Host range restriction of influenza A virus replication in duck intestine. In Options for the Control of Influenza IV pp1019-1021, 2001.
Watanabe T, Watanabe S, Kida H, Kawaoka Y. Replication-incompetent influenza virus for vaccines. In Options for the Control of Influenza IV pp1015-1017, 2001.　
Takada A, Kawaoka Y. Recent insights into the pathogenesis of Ebola hemorrhagic fever. Trends Microbiol 9:506-511, 2001.
Hatta M, Neumann G, Kawaoka Y. Reverse genetics approach towards understanding pathogenesis of H5N1 Hong Kong influenza A virus infection. Philos Trans R Soc Lond B Biol Sci 356:1841-1843, 2001

2000

Ito T, Kawaoka Y. Host range barrier of influenza A viruses, Vet Microbiol 74:71-75, 2000.
Neumann G, Kawaoka Y. Reverse genetics for the control of influenza. Influenza Bulletin 12:6, 2000.
Shortridge KF, Gao P, Guan Y, Ito T, Kawaoka Y, Markwell D, Takada A, Webster RG, Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. Vet Microbiol 74:141-147, 2000.
Goto H, Kawaoka Y. Assays for functional binding of plasminogen to viral proteins. Methods 21:159-163, 2000.
Nichol ST, Arikawa J, Kawaoka Y. Emerging viral diseases. Proc Natl Acad Sci U S A 97:12411-2, 2000.